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Abstract. Diffuse optical imaging and spectroscopy of the female breast is an area of active research. We review
the present status of this field and discuss the broad range of methodologies and applications. Starting with a
brief overview on breast physiology, the remodeling of vasculature and extracellular matrix caused by solid
tumors is highlighted that is relevant for contrast in optical imaging. Then, the various instrumental techniques
and the related methods of data analysis and image generation are described and compared including multi-
modality instrumentation, fluorescence mammography, broadband spectroscopy, and diffuse correlation spec-
troscopy. We review the clinical results on functional properties of malignant and benign breast lesions
compared to host tissue and discuss the various methods to improve contrast between healthy and diseased
tissue, such as enhanced spectroscopic information, dynamic variations of functional properties, pharmacoki-
netics of extrinsic contrast agents, including the enhanced permeability and retention effect. We discuss
research on monitoring neoadjuvant chemotherapy and on breast cancer risk assessment as potential clinical
applications of optical breast imaging and spectroscopy. Moreover, we consider new experimental approaches,
such as photoacoustic imaging and long-wavelength tissue spectroscopy.© The Authors. Published by SPIE under a Creative
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1 Introduction
Breast cancer is the most common cancer of women and the
second leading cause of death after cardiovascular disease in
many countries. About one in eight women will be diagnosed
with this disease during their lifetimes in the United States and
in European countries.1,2 Early diagnosis of breast cancer is
essential to ensure a high chance of survival for the affected
women. Therefore, an important task is to provide diagnostic
tools with high sensitivity for early detection of breast cancer
and high specificity to avoid false positive results.
Today’s first line imaging modality is x-ray mammography.
Several countries have implemented mammography screening
programs with the aim of early detection of the disease. How-
ever, the sensitivity of conventional x-ray mammography is only
about 75%.3 For radiographic dense breast tissue, which is more
common in younger women, the sensitivity can even drop below
50%.3 Considering that frequent x-ray exposure can promote the
development of cancer on a long time scale mammographic
screening is often discussed controversially. Magnetic resonance
imaging (MRI) of the breast offers higher sensitivity, yet its
specificity is rather poor.4,5 Moreover, it is characterized by
high costs and long examination times prohibiting screening.
Currently, this method is in use as an additional modality for
selected women with suspicious lesions. Similarly, breast ultra-
sound is often used as a supplementary tool. Its results are
strongly dependent on the examiner’s interpretation. In general,
biopsies, which are at the end of today’s breast cancer detection
clinical work flow, show a large number of false-positive cases
for the established imaging modalities.6,7
Besides the problem of detection and differentiation, tools
are needed to support or monitor the therapy of breast cancer.
A main part of treatment is the surgical removal of the cancerous
tissue. The today’s preferred way of breast-conserving surgery
requires methods to safely detect tumor margins. Furthermore,
the treatment of large cancers often starts with neoadjuvant
chemotherapy (NAC) to shrink the size of the tumor before sur-
gery. This shrinking process needs to be monitored by a suited
method. Currently, MRI is most often used to this end.8 However,
a less costly method not requiring application of contrast agents is
highly desirable, in particular for frequently repeated use.
During the last 15 years, optical imaging of the breast has
been investigated by many research groups as well as by com-
panies in order to develop tools that could yield considerable
contributions to the mentioned steps in breast cancer manage-
ment, i.e., to the detection of breast cancer, to its differentiation,
and to monitor its treatment. Starting from the idea to detect
breast cancer by near-infrared spectroscopy from contrast in
hemoglobin concentration and blood oxygen saturation, the
potential of optical imaging of the breast can now be realistically
assessed due to the large amount of data obtained from clinical
studies. However, definite conclusions are still difficult to draw,
as clinical studies were typically conducted with different instru-
ments, different methods of data analysis, and various clinical
protocols, making results often difficult to compare. Although
the original aim of developing a new tool for screening that
could compete with x-ray mammography could not be reached
so far, optical breast imaging has found potentially new areas of
application, such as monitoring of neoadjuvant therapy progress
and determination of risk populations for breast cancer develop-
ment. Furthermore, the application of contrast agents seems to
be a promising way for breast cancer imaging.*Address all correspondence to: Dirk Grosenick, E-mail: dirk.grosenick@ptb.de
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In this paper, we review the development of optical breast
imaging by near-infrared spectroscopy, including contrast agent
enhanced methodology. We start with a discussion of breast
physiology and with the main features of breast imaging instru-
mentation and data analysis approaches. Then, we consider the
available results on optical properties of the healthy breast and
of malignant and benign lesions and the various methods to
improve the contrast between healthy and diseased tissue. We
review research on monitoring neodjuvant chemotherapy and on
risk assessment as potential applications. And finally, we con-
sider new experimental approaches, such as photoacoustic im-
aging (PI) and long wavelength broadband spectroscopy.
2 Fundamentals of Optical Breast Imaging
2.1 Biomedical Background
2.1.1 Overall structure and composition of normal breast
tissue
Optical mammography and diffuse optical spectroscopy of the
human breast probe the absorption, scattering, and fluorescence
properties of various components of healthy and diseased breast
tissue. The human female breast consists mainly of glandular,
adipose, and connective tissue, together with blood and lym-
phatic vessels, and it contains several simple mammary glands
(lobes), each draining through a separate lactiferous duct. The
lobes branch into several lobules consisting of intralobular ducts
separated by rather loose (intralobular) connective tissue, con-
taining microvasculature and small lymphatic channels. Each
intralobular ductal tree terminates in a cluster of alveoli that
will differentiate to produce milk on exposure to lactogenic
hormones. The intralobular connective tissue and ductal net-
work are surrounded by the interstitial connective tissue, being
dense, less cellular, containing variable proportions of adipose
tissue and extracellular matrix (ECM), and representing over
80% of the human breast volume.9
Besides blood and lymphatic vessels, the connective tissue
(stroma) consists of various stromal cells and the ECM (see
Fig. 1), providing a scaffold for stromal cells (e.g., fibroblasts,
adipocytes, cells of the immune system, e.g., lymphocytes, mac-
rophages).10 The ECM is composed of water, proteins, and
polysaccharides.11 Proteoglycans (PGs) and fibrous proteins
(e.g., collagens, fibronectin, elastins) are the two main classes
of macromolecules of the ECM, forming an intricate interlock-
ing mesh.11 The polysaccharides glycosaminoglycans (GAGs)
are usually attached to ECM proteins to form PGs. PGs fill the
majority of the extracellular interstitial space within the tissue in
the form of a hydrated gel.11 PGs have a net negative charge that
attracts sodium ions and in consequence water, keeping the
ECM and resident cells hydrated. Unlike other GAGs, the poly-
saccharide hyaluronic acid (or “hyaluronan”) contained in the
ECM is not bound to matrix proteins. Hyaluronic acid in the
extracellular space confers upon tissues the ability to resist com-
pression providing a counteracting swelling force by absorbing
significant amounts of water. Collagens constitute the main
structural element of the ECM and, together with other fibrous
proteins, provide mechanical strength and elasticity to the
tissue.11 Nonactivated tissue fibroblasts secrete various ECM
proteins (collagens and elastins) and PGs including hyaluronic
acid.11 The ECM, containing various peptides, e.g., growth fac-
tors and enzymes, is being constantly remodeled for tissue
homeostasis. Such remodeling is regulated by a careful balance
between intracellular matrix synthesis, secretion, modification,
e.g., crosslinking of collagens by lysyl oxidases (LOX) and
enzymatic degradation, e.g., by matrix metalloproteases
(MMPs).12 The ECM not only represents scaffolding for the
stromal cells but also conveys biochemical and biophysical sig-
nals to cells.
Fig. 1 Structure and function of ECM in (a) normal and (b) tumorous glandular epithelial tissue (e.g.,
breast). (Reprinted with permission from Frantz et al.11)
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2.1.2 Abnormal vasculature and lymphatics of solid
tumors
Solid tumors are not simply a collection of neoplastic cells but
have been considered to be abnormal organs, with abnormal
vasculature and lymphatics, abnormal ECM, and populations
of stromal cells differing from normal host tissue.10,13 The vas-
culature of solid tumors differs distinctly from that of surround-
ing host tissue. Vasculature in normal tissue is arranged in a
hierarchy of arteries–arterioles–capillaries–venules and veins,
and grows under strict control of intervessel distances to
ensure sufficient supply of oxygen and nutrients to cells by
diffusion after extravasation, whereas tumor vasculature devel-
ops in a chaotic manner without such control, leading to chaotic
interconnectivity of vessel segments and spatial vascular hetero-
geneity. In solid tumors, necrotic regions and regions of low
microvessel density may occur, whereas tumor blood vessels
are more abundant at the tumor–host interface.14
Tumors may co-opt existing host vasculature for supply of
oxygen and nutrients,15,16 yet new vasculature must generally
develop for tumors to grow beyond 1 to 2 mm3 in size.17 New
blood vessels may be grown from existing vasculature by angio-
genic sprouting, followed by growth of sprouts and their fusion
with existing vessels to form new perfused blood vessels (neo-
angiogenesis).16,18,19 Vascular sprouting is initiated by vascular
epithelial growth factor (VEGF), which is secreted by, e.g.,
hypoxic tumor cells. VEGF works in concert with other growth
factors, e.g., angiopoietin-1 (ANG-1) and angiopoietin-2
(ANG-2). ANG-1 is involved in vessel maturation.19 On the
other hand, ANG-2 disrupts the connections between the endo-
thelium and perivascular cells and thus promotes cell death and
vascular regression. Yet, in conjunction with VEGF, ANG-2
promotes neovascularization. By destabilizing existing vessels,
ANG-2 allows for the formation of sprouts, thus contributing to
neoangiogenesis, provided VEGF is present at sufficient con-
centration.16,19,20 In solid tumors, guidance proteins (EphB4)
have been shown to act as negative regulators of blood vessel
branching and vascular network formation, switching the vascu-
larization program from sprouting angiogenesis to circumferen-
tial vessel growth.21 Neovascularization in solid tumors involves
many complex processes of different origin and molecular
pathways,22 whereas processes of angiogenesis are strictly
controlled under physiological conditions; this is no longer
true in solid tumors, and tumor vessels turn out to be immature,
fragile, tortuous, dilated, with uneven diameters, and known to
form (large diameter) arteriovenous shunts. Often, it is even
difficult to distinguish arterioles from venules in solid tumors,
i.e., the classification of tumor vessels as arterioles, capillaries,
and venules is no longer adequate.13,14,18,23
Tumor cells that are considerably farther apart from nearby
capillaries than the diffusion limit of oxygen (typically 100 to
200 μm) suffer from chronic (diffusion limited) hypoxia.
Furthermore, the structurally abnormal tumor vasculature results
in spatially and temporally heterogeneous blood flow, affecting
tissue oxygenation (acute or perfusion-limited hypoxia).24 From
intravital dorsal window microscopy on tumor models, it is
known that blood flow through tumor capillaries is frequently
sluggish and at times may even be stationary and reverse
direction.23 It follows that blood flow through tumors may not
follow a constant unidirectional path. In addition, red blood cell
(RBC) flux varies greatly among tumor vessels; many tumor
vessels do not carry RBCs but contain plasma only.24 Solid
stress, caused by tumor cell proliferation and increased ECM
deposition in tumors, may compress or block existing vascula-
ture, impeding blood flow and, hence, the supply of oxygen and
nutrients.9,25–27
Tumor hypoxia is associated with poor prognosis, because it
causes resistance to standard therapies and promotes more
aggressive tumor phenotypes.28 Hypoxic tumor cells are known
to be resistant to ionizing radiation, since oxygen is needed to
stabilize radiation-induced DNA defects and, in addition, are
considered to be resistant to some anticancer drugs.28,29 Further-
more, T-cells are dependent on normal oxygen levels for migra-
tion in tumor tissue, suggesting that hypoxia indirectly regulates
antitumor immunity by restricting T-cell access.10
Tumor vessels may exhibit high permeability to macromole-
cules, e.g., to plasma proteins such as albumin.18,30 Generally,
lymphatic drainage is impaired in tumors, since lymphatic ves-
sels are sparse or even absent. Because of the leakiness of tumor
vasculature, interstitial fluid pressure rises from, e.g., 0 mmHg
in normal breast tissue up to 30 mmHg in breast cancers or
even higher,13 impeding extravascular fluid flow and transport
of extravasated macromolecules including chemotherapeutics,
causing the so-called enhanced permeability and retention (EPR)
effect.30,31 Macromolecules administered intravenously or small
molecules, e.g., drugs that associate with plasma proteins, may
not extravasate from normal vasculature, yet may leak into the
interstitial matrix from tumor vasculature due to its enhanced
permeability and stay there because of impaired lymphatic
drainage.
2.1.3 Abnormal extracellular matrix of solid tumors
It has long been known that tumor-derived ECM is biochemi-
cally distinct in its composition compared with normal ECM
(Fig. 1).12 Breast cancer progression is associated with changes
in ECM composition, with inflammatory cell infiltration, and
differentiation of fibroblasts.9 Tumor-derived ECM differs
from that of the host tissue, owing to the disruption of the bal-
ance between ECM synthesis and secretion and owing to alter-
ations in the normal levels of matrix-remodeling enzymes, such
as MMP and LOX.12 The ECM remodeling observed in tumors
includes increased deposition of collagen, fibronectin, PGs,
substantial MMP-dependent cleavage, and increased levels of
LOX-dependent matrix crosslinking. There is evidence for an
increased deposition of ECM in hypoxic tumor regions.32
Differentiated fibroblasts (e.g., myofibroblasts) deposit large
amounts of ECM proteins.11 The expression of MMPs is often
highly upregulated in solid tumors with MMPs produced by
myofibroblasts and tumor cells.11 ECM deposition and leuko-
cyte infiltration are often very pronounced at the tumor-stroma
border.10 The majority of increased tumor and adjacent tissue
stiffness occur as a result of increased ECM deposition.12
Furthermore, increased LOX activity results in increased ECM
stiffness.12 As illustrated in Fig. 2, the expanding tumor mass
exerts compressive stress (tissue solid stress) on the surrounding
tissue, on the ECM, on intratumoral vasculature and lym-
phatics.9,25 NIR imaging is directly affected by the modifications
of the ECM occurring in tumors, resulting in changes of the tis-
sue absorption spectrum. For example, additional deposition of
collagen increases long-wavelength (1060 nm) absorption, while
tissue solid stress on tumor vasculature may affect blood flow,
resulting in changes of oxyhemoglobin concentration and corre-
sponding modifications of the absorption spectrum.
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2.1.4 Expected solid tumor-host optical contrast
Within the optical window, extending from about 635 up to
1060 nm breast tissue optical spectroscopy yields the absorption
coefficient μaðλÞ and reduced scattering coefficient μ 0sðλÞ of the
host and tumor tissue. From average absorption coefficients
μaðλÞ, concentrations of the main tissue constituents deoxyhe-
moglobin (HbR), oxyhemoglobin (HbO2), and thus, total hemo-
globin HbT ¼ HbRþ HbO2, water, lipids, and collagen can be
inferred using Beer’s law. Total tissue hemoglobin concentra-
tion, HbT, can be converted to vascular volume fraction rBV
(vascular volume density) according to HbT ¼ MCHC × H ×
rBV where MCHC is the mean corpuscular hemoglobin concen-
tration and hematocrit H is assumed to be homogeneous within
the vasculature. Because of angiogenesis and circumferential
vessel growth occurring in tumors, one expects higher vascular
volume fraction and thus higher total tissue hemoglobin concen-
trations in tumorous compared to host tissue HbTðTÞ > HbTðNÞ
(see Sec. 4.1). Tissue blood oxygen saturation, defined as
StO2¼ HbO2∕HbT, depends not only on vascular structure
but also on transvascular oxygen loss, i.e., on tissue metabolic
rate of oxygen consumption and on vascular oxygen supply, i.e.,
on perfusion. From tumor biology, the concentration of collagen
is expected to be higher in breast tumors compared to surround-
ing host tissue. Likewise, because of the additional deposition of
the ECM in tumors and the hydrophilic nature of PGs contained,
higher water content in breast tumors is predicted.
Apart from absorption, light scattering in tissue provides
information on tissue structure and composition. Light scatter-
ing in tissue is dominated by Mie scattering and, therefore,
probes density and size of biological cells; however, scattering
by other tissue structures, such as collagen fibrils, cannot be
excluded. Because of tumor cell proliferation and infiltration of
various cells (e.g., inflammatory cells, differentiated fibroblasts)
into the tumor stroma, cell density and, hence, the reduced scat-
tering coefficient μ 0s are expected to be increased in tumors com-
pared to their surrounding host tissue. Furthermore, formation of
large modified collagen bundles likely affects photon scattering
(see Fig. 2). As discussed in Sec. 4.1, most of these predictions
are borne out by experimental data.
2.2 Historical Development of Optical Breast
Imaging
First attempts to see suspicious lesions in the female breast using
visible light were reported by Cutler in 1929.33,34 The breast was
transilluminated by holding a small size powerful lamp against
the lower surface of the breast and by observing shadows of the
light on the upper breast side by eye that arose from high-
absorbing tissue structures. In the 1970s and 1980s, transillumi-
nation imaging of the breast was further developed by using
improved light sources in combination with light detection by
sensitive films or video cameras.35–39 However, several clinical
studies showed that sensitivity and specificity of the so-called
lightscanning or “diaphanography” method were low in com-
parison to x-ray mammography.40–43 The lightscanning approach
was very simple to apply, but it had major intrinsic disadvan-
tages, including the absence of discrimination between scatter-
ing and absorption of the tissue and the limited exploitation of
spectral information.
New efforts in optical breast imaging started in the 1990s. At
that time, mathematical models of light propagation in tissue
became available that permitted separation of the scattering
and the absorption properties of the tissue. In this way, absorp-
tion properties could be exploited by the methods of near-infra-
red spectroscopy to determine the composition of the tissue, i.e.,
to measure the concentrations of the main tissue absorbers
including blood oxygen saturation. Basic concepts of optical
breast imaging developed at this time are valid until today.
2.3 Classification of Optical Breast Imagers
Normally, optical images of the breast are obtained by switching
through a sufficient number of point-like light sources realized
by illuminated optical fibers and, for each source, detecting the
light at one or several suited detector positions. The instruments
for optical breast imaging and spectroscopy can be classified
with respect to the temporal profile of the laser radiation
employed and according to their measurement geometry.
Furthermore, a few instruments have been designed to detect
fluorescence arising from an exogenous contrast agent. The
three well-known groups of instruments are time-domain, fre-
quency-domain, and continuous-wave (CW) systems. Briefly,
time-domain systems measure the broadening of short (picosec-
ond) laser pulses after propagation through the tissue. Absorp-
tion coefficients μa and reduced scattering coefficients μ 0s of the
tissue can be derived from the analysis of the detected pulse
shape using an appropriate model of photon propagation. These
coefficients characterize the tissue volume sampled by photons
depending on the particular source–detector combination. For
source–detector separations of a few centimeters, the width
of the broadened pulses amounts typically to a few nanoseconds.
A well-suited technique for the detection of these pulses is
time-correlated single-photon counting. In the past, hardware
Fig. 2 Extrinsic and intrinsic forces on (a) normal and (b) tumorous glandular epithelial tissue (e.g.,
breast). (Reprinted with permission from Frantz et al.11)
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for time-domain systems was expensive. However, it is now
becoming possible to perform time-resolved data acquisition
with more cost-competitive instrumentation.
Frequency-domain systems use intensity-modulated laser
radiation and measure its demodulation and phase shift after
passing through tissue. In principle, it is sufficient to perform
such measurements at one modulation frequency to separate
the absorption and the scattering coefficient of the sampled
tissue volume. Typically, a modulation frequency of about
100 MHz is chosen. Frequency-domain measurements corre-
spond to investigating the Fourier spectrum of time-domain
measurements at one frequency. By employing several modula-
tion frequencies up to at least 1 GHz, the information content of
frequency domain measurements increases and becomes com-
parable to that of typical time-domain investigations.
CW systems use continuously emitting lasers or light-emit-
ting diodes at several near-infrared wavelengths, or broadband
light sources. The instruments detect the attenuation of the trans-
mitted light. More specifically, the CW technique yields the
attenuation coefficient κ ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃμa∕D
p
, which is a combination of
the absorption coefficient μa and the diffusion coefficient D ¼
1∕3μ 0s . To obtain absolute values of the absorption coefficients,
prior knowledge on the reduced scattering coefficient is
required, e.g., from additional investigations with the frequency-
domain or time-domain technique or by using representative
values from literature. However, because light scattering domi-
nates over absorption within the optical window, the latter
approach may lead to systematic errors. Alternatively, it is pos-
sible to assess both absorption and scattering properties by per-
forming CW measurements at more than one source–detector
separation, which has been used, e.g., to obtain properties of
small (almost homogeneous) tissue regions.44 Generally, it is
also possible to exploit spectral features for the separation of
absorption and scattering by using specifically selected optical
wavelengths.45 The main advantage of the CW approach is that
light sources and detectors are comparably cheap. Therefore,
such systems can be equipped with a large number of source and
detector positions at low costs.
The geometry for optical breast imaging can be divided into
three main groups (Fig. 3). In one approach, the breast is com-
pressed between two parallel plates. This geometry is very close
to the concept of x-ray mammography. It offers a simple way to
compare an optical transillumination image with a correspond-
ing x-ray mammogram. A second approach consists of investi-
gating the freely pending breast with the woman being in prone
position. This geometry has high similarity with MRI of the
breast. The third basic approach is the use of a handheld
probe that can be positioned at selected locations of the breast
or moved over its surface similar to a breast ultrasound detector.
It is obvious that these three geometries offer the possibility
for combining optical imaging with x-ray, MR, or US breast
imaging, which was pursued by several groups, mainly to
gain prior information on spatial tissue composition, lesion
size, and position when analyzing their optical and functional
properties.
3 State-of-the-Art Instrumentation and Data
Analysis
3.1 Overview on Optical Breast Imagers
Figure 3 shows several examples of the measurement geometry
and the source–detector arrangements that were realized in
instrumentation for clinical studies on optical breast imaging.
A simple way to realize the compression geometry is the
application of two transparent plates with variable distance
[Fig. 3(a)]. Optical transillumination images of the breast can
Fig. 3 Examples of measurement geometries: (a) parallel-plate geometry with moving source fiber and
few detector fibers in transmission and reflection,46 (b) parallel-plate geometry with fixed source and
detector fibers (left) and CCD camera detection (right) (reprinted with permission from Choe et al.47),
(c) freely pending breast geometry with 255 source and 255 detector fibers (© 1999 IEEE. Reprinted
with permission from Colak et al.48), (d) freely pending breast with 32 sources and 32 detectors (reprinted
with permission of Optical Society of America from Enfield et al.49), (e) circular arrangement of 48 fibers in
three rings with 16 translation stages to bring the fibers in contact with the tissue (reprinted with permis-
sion from Pogue et al.50), and (f) handheld probe (reprinted with permission from O’Sullivan et al.51).
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be obtained by moving a source fiber on one side and a detector
fiber on the other side in tandem. Such systems have first
been developed by the German companies Siemens and Carl
Zeiss.52,53 Both systems were equipped with frequency-domain
instrumentation. Later, the Physikalisch-Technische Bundesan-
stalt54 and the Politecnico di Milano55 used this geometry to
build-up the first time-domain scanning optical mammographs.
At Tufts University, the compression geometry has been
employed more recently in a hybrid instrument combining
frequency-domain measurements at a few near-infrared wave-
lengths with broadband CW spectroscopy56 and in an instrument
using solely CW radiation.57 With a scanning step size of a few
millimeters or even less, typically, more than 1000 source–
detector combinations (scan positions) are sampled.
As an example for the parallel plate geometry, the schematic
in Fig. 3(a) shows the latest source–detector fiber arrangement
of the PTB instrument with several detection fibers in transmis-
sion and also detection fibers in reflection.46 The various
fibers in transmission permit the detection of transillumination
images at the implemented optical wavelengths under different
projection angles, which can be exploited to reconstruct three-
dimensional (3-D) images of the tissue.46,58 The additional
detection fibers in reflection can be used to improve the 3-D
resolution close to the surface, as shown in phantom experi-
ments.59 However, with a transparent plate, only distances from
the source fiber below, typically, 1 cm can be exploited due to
multiple reflections occurring within the plate. Figure 3(a)
shows a second source fiber (dashed line), that was added to
the PTB optical mammograph for fluorescence measurements.
The tandem scanner concept with several offset fibers in trans-
mission is also employed in the latest version of the CWoptical
mammograph developed at Tufts University.57
Figure 3(b) illustrates the parallel-plate instrument developed
at University of Pennsylvania. This hybrid CW-frequency
domain device uses the compression geometry with a source–
detector arrangement optimized for tomographic reconstruction.
The patient is in the prone position with both breasts hanging in
a tank filled with a scattering fluid. The opaque compression
plate on the left-hand side is equipped with 45 fixed source
fibers and 9 fixed detector fibers. The frequency-domain
approach is employed to measure the diffusely reflected light
at four wavelengths. The CCD camera on the right-hand side
in Fig. 3(b) is used to measure the diffuse transmittance of
the breast by the CW approach at up to six wavelengths.47
This device was extended with an option for fluorescence mea-
surements using indocyanine green (ICG) as contrast agent.60
There were also two time-domain devices developed that use
the parallel-plate geometry with matching fluid chamber,
the commercial system Softscan of Advanced Research
Technologies (ART) Inc., Montreal,61 and a laboratory proto-
type at the Physikalisch-Technische Bundesanstalt Berlin.62
Both these devices employed the concept of scanning source
and detector fibers along transparent plates. Depth resolution
was achieved by either offset detection channels in transmission
similar to Fig. 3(a) or by two CCD cameras similar to Fig. 3(b).
The PTB device was also capable of performing fluorescence
investigations. The company DOBI Medical International Inc.
developed the parallel-plate device ComfortScan for imag-
ing pressure-induced changes in the blood oxygen saturation
of tumors. This instrument uses flat-field illumination at
640 nm by LEDs and CCD camera detection of the transmitted
light.63
Figures 3(c) and 3(d) show examples of devices with a cup-
like chamber for investigations of the freely pending breast. The
cup in Fig. 3(c) belongs to the CW instrument built by Philips,
Eindhoven. In this device, a total of 255 source fibers and 255
interleaved detection fibers were used to reconstruct the tissue
attenuation coefficient at three optical wavelengths.48 The same
geometry was used in the fluorescence instrument developed
about 10 years later.64 The time-domain instrument in Fig. 3(d)
was built at the University College London. It is equipped with
32 source fibers and 32 detection fiber bundles and provides 3-D
images of the absorption and scattering properties at two
wavelengths.49 Both these devices with cup geometry use a scat-
tering fluid to get high quality optical coupling and to work with
a well-defined geometry for reconstruction of the optical proper-
ties. In order to account for breasts of different sizes, cups with
different diameters can be used.
At Dartmouth College, a frequency-domain instrument with
six optical wavelengths was developed for investigations on the
freely pending breast that does not need a scattering fluid [see
Fig. 3(e)]. Here, 48 fibers, which are arranged on three rings, are
brought in contact with the tissue under slight pressure.50 In a
newer version, the wavelength range of the device was extended
up to 948 nm employing CW lasers.65 The breast imager devel-
oped by NIRx Technologies uses the same principle of pressure-
induced optode contact. From these four wavelengths, the CW
instrument permits simultaneous investigations on both breasts
of the patient. It has been designed for dynamic investigations to
record the physiological response of the breast tissue to specific
interventions, such as the Valsalva maneuver or to dynamically
observe the effect of a contrast agent bolus.66,67 The company,
Imaging Diagnostics Systems, Inc., Fort Lauderdale, followed
the principle of CT scanners and developed devices in which the
freely pending breast of the patient in prone position is scanned
by moving a laser beam and a detector array circularly around
the tissue. By changing vertical positions, contiguous slices of
the breast are acquired at one optical wavelength.68,69 Hereby,
the detectors are not in contact with tissue. An extended version
of these devices was prepared for fluorescence investigations.
Detection limits of diffuse optical tomography systems were
investigated theoretically and numerically.70,71 The method con-
sists of analyzing raw numerical phantom data by means of a
chi-square test, obtained from forward simulations together
with a realistic noise model, derived from the system hardware.
Both parallel-plate and cup geometries were compared with
respect to detection limits of heterogeneities at various positions
within the tomographic volume investigated. In cup geometry,
low detection sensitivity was obtained at the upper center of the
cup [cf., Figs. 3(c) and 3(d)], i.e., close to the chest wall, where
the tissue is exclusively sampled by source–detector combina-
tions with large separations. In slab geometry, detection sensi-
tivity shows only small variations between the outer and the
inner tissue regions, since the breast is sampled with constant
source–detector separation. Generally, for smaller breast sizes,
lesions of 5-mm diameter could be detected in almost all parts of
the compressed breast (parallel-plate geometry) and in the outer
parts of the uncompressed breast (cup geometry), whereas for
larger breasts, the detection limit moved toward 7.5-mm lesion
size when a lesion-to-background absorption contrast of 2∶1
was assumed.
The third group of optical breast imagers comprises devices
with handheld probes. As an example, Fig. 3(f) shows the probe
of the diffuse optical spectroscopic imaging (DOSI) device
Journal of Biomedical Optics 091311-6 September 2016 • Vol. 21(9)
Grosenick et al.: Review of optical breast imaging and spectroscopy
developed at the University of California, Irvine.51,72 This device
combines the frequency-domain and the CW approach. It con-
tains two source–detector pairs. The first one is used to perform
frequency-domain measurements at six optical wavelengths
ranging from 650 to 860 nm. In contrast to the frequency-
domain instruments discussed above, the modulation frequency
is varied here from 50 to 1000 MHz. Therefore, the amount of
information obtained for the sampled tissue volume is compa-
rable to that of time-domain approaches discussed above. The
second source–detector pair is connected to a tungsten halogen
white-light source and a spectrometer to record broadband
reflectance spectra from 650 to 1000 nm. The scatter power law:
EQ-TARGET;temp:intralink-;e001;63;620μ 0sðλÞ ¼ μ 0sðλ0Þðλ∕λ0Þ−b; (1)
which is fitted to frequency-domain data at the six discrete
wavelengths, provides a scatter correction for the CW reflec-
tance spectra. In a second step, the absorption spectra are
extracted by best fitting the corrected CW reflectance spectra
to the photon diffusion model and used to fit the chromophore
concentrations. To obtain spatially resolved information, the
probe is positioned, e.g., at steps of 10 mm, along a line or a
two-dimensional (2-D) grid on the breast at the (known) lesion
position with the patient in supine position.73
At the University of Pennsylvania, a handheld CW imager
was used for breast imaging with a three wavelengths LED
source and eight surrounding silicon diode detectors 4-cm apart
from the source.74 Another CW device was developed by
ViOptix, Inc., Fremont.75 Handheld probes have also been
used for blood flow characterization in breast tissue and tumors
employing diffuse correlation spectroscopy (DCS; cf. Sec. 3.5).
A detailed overview about the various handheld NIR devices for
breast imaging and other applications can be found in the review
by Erickson and Godavarty.76
3.2 Multimodality Imaging
Several groups have combined optical breast imaging with other
clinical breast imaging modalities. Hereby, the conventional
clinical modality provides structural information about the
breast tissue that is exploited in the reconstruction of the optical
and physiological properties. In this way, problems of low spa-
tial resolution and diffuse blurring of reconstructed optical data
can be overcome, and optics can provide, e.g., metabolic infor-
mation about lesions not accessible by the conventional modal-
ities. At the University of Connecticut, a handheld probe device
has been developed for combined investigations of breast
tumors by NIR light and ultrasound. This probe contains a
commercial US detector array together with 12 source and 8
detection fibers for diffuse reflectance frequency-domain mea-
surements at several source–detector distances.77 In the present
version, three optical wavelengths between 660 and 830 nm are
used.78
The combination of optical and ultrasound measurements in
a handheld probe is technically simple, whereas the combination
of optical and MR measurements is more challenging. To avoid
interference of the optoelectronic components with the high
magnetic field, long fibers or fiber bundles have to be used to
deliver and collect the light inside the MR bore. Furthermore,
the restricted space inside the bore limits the number of source
and detector fibers that can be installed. The first demonstration
of concurrent optical and MR imaging of breast tissue was
reported by Ntziachristos and Ma,79 who placed a parallel-plate
patient interface for time-resolved transmittance measurements
inside the MR tomograph. This instrument allowed comparison
of contrast-enhanced optical absorption imaging with ICG ver-
sus dynamic contrast enhanced MR imaging80 and provided
intrinsic hemoglobin and oxygen saturation contrast StO2 for
malignant and benign breast lesions.81 At Dartmouth College,
a 16 fiber ring holder interface was applied inside the MR scan-
ner for simultaneous frequency-domain optical and MR interven-
tions.82 During reconstruction of the optical images, the structural
information from the MR investigations was used as prior infor-
mation. This group also reported successfully incorporating water
and fat information from MR imaging to improve the accuracy of
the reconstructed hemoglobin concentration.83
At the Massachusetts General Hospital, a combined optical
and x-ray breast imager was developed that uses the parallel-
plate geometry. Optical measurements are performed in trans-
mittance by a hybrid frequency-domain and CW approach
using a source–detector grid designed for 3-D reconstruction of
the optical properties. The device can also be applied for func-
tional monitoring of the breast tissue.84
3.3 Data Analysis and Reconstruction
One aim of data analysis is the generation of optical mammo-
grams, i.e., the generation of 2-D or 3-D images that display
lesions and structures inside the breast with high contrast.
Another aim is the determination of the optical and physiologi-
cal parameters of lesions and of healthy breast tissue. Hereby,
the generation of images is not really required. Generally, optical
mammograms can provide such values. However, the accuracy
of values characterizing lesions is often limited by the diffuse
blurring and by partial volume effects. These limitations can
be overcome by using prior information about the size and
location of the lesions together with adequate heterogeneous
models.
The generation of optical mammograms for the circular
tomographic geometry requires a reconstruction of the optical or
physiological properties of the breast. For the parallel-plate
devices, reconstruction can also be applied, but it is not manda-
tory. Since the distance between source fiber and the detection
fiber in scanning devices with parallel-plate geometry is the
same at all scan positions, data at each scan position can be ana-
lyzed independently.
Figure 4 illustrates some general features of optical mammo-
grams obtained by the various data analysis methods. Transil-
lumination images from parallel-plate instruments [Figs. 4(a)–
4(c)] often exhibit not only the carcinoma but also superficial
blood vessels and other localized regions of high vasculariza-
tion. Reconstructed slices from parallel-plate instruments show
more blurred structures [Figs. 4(d) and 4(e)]. Similarly, recon-
structed images from circular tomographic measurements
[Figs. 4(f) and 4(g)] display the carcinoma often within a non-
uniform background with additional structures showing high
correlation to the source and detector fiber positions.
3.3.1 Homogeneous models
Together with time-domain parallel-plate instruments, so-called
late-gate and early-gate intensity images are used to generate
optical mammograms showing absorbing lesions like carcinomas
and lesions with reduced light scattering like cysts with high
contrast. Hereby, the different effects of localized scattering and
absorbing objects on time-resolved transmittance measurements
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are exploited.90 The late-gate intensity is mostly sensitive to
absorption properties, and consequently, a late-gate image at
a certain wavelength displays the spatial distribution of the
major absorber at that wavelength. Thus, late-gate intensity
mammograms at wavelengths around 800 nm are directly cor-
related to the distribution of (total) hemoglobin in the tissue,
whereas late-gate mammograms at wavelength between 650
and 690 nm are more sensitive to the distribution of deoxyhe-
moglobin in tissue [Fig. 4(a)]. Correspondingly, mammograms
taken at about 925 and 975 nm are correlated to the local dis-
tribution of lipids and water in the tissue, respectively. In fre-
quency-domain measurements, the absorption properties of
tissue are typically displayed by optical mammograms showing
demodulation, whereas phase information yields mammograms
related to scattering properties. The visual contrast of absorbing
objects in late-gate or demodulation images can be enlarged by
plotting reciprocal values of these quantities or using a second-
derivative method.53,54,91
However, simple intensity mammograms at different wave-
lengths give only qualitative information about optical and
physiological properties of lesions. In order to determine these
properties quantitatively, time-domain or frequency-domain
data have been analyzed by different models of light propaga-
tion. A simple approach to determine the tissue optical proper-
ties at each scan position is the application of the diffusion
model for the homogeneous infinite slab. In this way, optical
mammograms showing absorption coefficients and reduced
scattering coefficients can be generated. From corresponding
data at different wavelengths, maps of hemoglobin concentra-
tion HbT and tissue blood oxygen saturation StO2, water,
lipid, and collagen content can be derived relying on Beer’s
law. Information on number density and equivalent size of the
scattering centers (typically cell organelles, membranes, and so
on) can be obtained from the dependence of the reduced scatter-
ing coefficients on wavelength together with appropriate Mie
calculations.92,93 To improve the robustness and stability of
the fitting procedure that aims at estimating a rather high number
of unknowns from data collected at few wavelengths, a spec-
trally constrained global fitting procedure has also been effec-
tively applied.94 Specifically, the concentrations of oxy- and
deoxyhemoglobin, water, lipids, and collagen, together with
the reduced scattering coefficient at 600 nm and scattering
power b, were fitted directly to time-resolved transmittance
curves measured at 7 wavelengths, using the Beer law to relate
the absorption properties to the concentrations of the main tissue
constituents and the approximation to Mie theory to model the
scattering properties.
When a homogeneous model is applied, the contrast between
lesions and the surrounding tissue is underestimated since the
lesion typically fills only part of the banana-like volume
between source and detector (partial volume effect). In order
to enhance the contrast in these maps, the application of a sec-
ond-derivative approach was proposed.95
The discussed models for the parallel-plate geometry need to
be improved at the edges of the breast since the breast of
decreasing thickness no longer fills the space between both
glass plates. To avoid artifacts, distributions of times of flight
can be scaled using the mean times of flight of the detected pho-
tons as a rough measure of the tissue thickness at the various
scan positions.96 This correction works also for fluorescence
measurements.46 In frequency domain, demodulation data can
be corrected for edge effects by exploiting the measured phase
information.97
Measurements in reflection geometry with the handheld
probe, as shown in Fig. 3(f), have been analyzed by using the
diffusion model for the homogeneous semi-infinite medium.98
Fig. 4 Examples of absorption and HbT optical mammograms of patients with carcinomas (labeled by
arrows or lines): (a) late-gate transillumination image at 670 nm from a parallel-plate instrument display-
ing a 3.5-cm carcinoma (from Rinneberg et al.85); (b) transillumination image at 785 nm from a parallel-
plate instrument displaying difference in absorption coefficient Δμa from average background analyzed
within an inhomogeneous model (from Quarto et al.86); (c) HbT transillumination image with 3.9-cm car-
cinoma from a CW parallel-plate instrument (reprinted with permission from Anderson et al.87), (d) recon-
structed slice of relative total hemoglobin concentration (designated rTHC) with a 2.2-cm carcinoma from
a parallel-plate instrument with matching fluid (reprinted with permission from Choe et al.47), (e) recon-
structed slice of HbT with a 2.5-cm carcinoma obtained with prior knowledge from x-ray mammography
(reprinted with permission of the Radiological Society of North America from Fang et al.88), (f) recon-
structed slice (HbT map) with a carcinoma about 4 cm in size (reprinted with permission from Wang
et al.65), and (g) reconstructed absorption image with carcinoma (indicated by yellow circle) from
a CW tomographic instrument with matching fluid (image reproduced from van de Ven et al.89).
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Also, in this analysis, the contrast of the lesion to the surround-
ing tissue is underestimated due to partial volume effects. By
plotting the results obtained at different positions of the probe,
a mammogram with a small number of pixels is obtained.73
3.3.2 Heterogeneous models
More realistic values of lesion optical properties and functional
parameters from parallel-plate devices have been obtained by
the application of inhomogeneous models considering the lesion
as an object in an otherwise homogeneous background medium.
One approach is the model of diffraction of photon density
waves by a spherical object.99 Furthermore, a random walk
model has been used to derive tumor optical properties.100 Other
approaches are perturbation models like the first-order Born
approximation or an empirical Padé approach.101,102 Since the
true shape of the lesion is typically not known, the spherical
shape has been assumed in these models. The latter two models
have also been employed to generate optical mammograms by
assuming a virtual sphere of predefined size located in the mid-
plane of the breast. In this way, the partial volume effect of the
homogeneous model discussed above is reduced and the lesion
contrast in the optical mammogram is improved. Generally, low
order perturbation models are at their limit of validity in a large
number of cases, since lesion size and absorption contrast can
become large.103 Recently, a higher order perturbation model
has been employed for the analysis of the optical and functional
parameters of malignant and benign lesions [see Fig. 4(b)].86
The results of the inhomogeneous models strongly depend
on the assumptions about the size and the location of the lesion
(distance to the parallel plates). The latter information can be
easily derived from measurements with offset fibers [cf.,
Fig. 3(a)].99 However, the size cannot be reliably determined
from the optical measurements due to the diffusive nature of
the light propagation. Therefore, often the size information from
conventional clinical imaging modalities or from pathological
findings has been used as prior information. Hereby, one should
have in mind that the extension of the vascular bed of a tumor,
which is responsible for the optical contrast, could deviate from
the clinical size estimation.
3.3.3 Reconstruction of optical properties and functional
parameters
Optical mammograms based on the circular tomographic geom-
etry are obtained by 2-D or 3-D reconstruction of optical proper-
ties and functional parameters. Typically, the diffusion model is
used as forward model. Arbitrary geometries of the breast can be
handled by the finite-element method. Time-domain data from
the freely pending breast covered by a matching fluid have been
analyzed by applying the TOAST software package.49 At
Dartmouth College, a frequency-domain implementation of
the finite element method was employed.104 Later, this model
was developed toward a spectrally constrained approach that
directly fits the functional parameters, hereby exploiting the
scatter power law [Fig. 4(f)].105 Philips used a back projection
algorithm to reconstruct the attenuation coefficients for their
CW instrument.48 In their fluorescence, mammograph recon-
struction of attenuation data was performed by a linear Rytov
approximation assuming constant scattering [Fig. 4(g)]. For
reconstruction of the fluorescence data, a Born approximation
was used.64 Data from the dynamic breast imager of NIRx are
analyzed by a linear perturbation method, too.66
Data from parallel-plate geometry instruments have also
been analyzed by reconstruction. Due to the well-defined breast
shape, finite differences on a rectangular grid can be applied
here. Ntziachristos et al.80 used the linear Rytov approximation
to reconstruct absorption changes after application of the con-
trast agent ICG. Since the iteration algorithm did not converge,
a calibration procedure was employed.80 To analyze the CW
data from the University of Pennsylvania instrument shown in
Fig. 3(b), Culver et al.106 described an iterative model based on
the Rytov approximation of the diffusion equation to reconstruct
tissue absorption. Later, data from the University of Pennsyl-
vania instrument were analyzed by a multispectral approach
based on finite elements to derive directly the oxy- and de-
oxyhemoglobin concentrations [Fig. 4(d)].47 With this multi-
spectral method, the basic problem of separating absorption
and scattering properties from CW data could be overcome.107
The reconstruction method was then extended to analyze fluo-
rescence data recorded with ICG.60 Dierkes et al.58 employed a
fast linear Rytov approximation to reconstruct both absorption
and scattering mammograms from time-domain data. Ziegler
et al.59 developed a nonlinear algorithm based on the Rytov
approximation for simultaneous reconstruction of absorption
and scattering properties. Another approach for the generation
of 3-D optical mammograms in the parallel-plate geometry
is the application of tomosynthesis. This method has been
applied to both intrinsic contrast and ICG fluorescence contrast
investigations.46
Reconstruction based on diffusion theory is usually per-
formed with regularization,108 i.e., the analysis yields a solution
of the inverse problem with minimal deviation to a reference
dataset, which is either a phantom dataset, e.g., the matching
fluid surrounding the breast in several devices, or an average
dataset for the breast under investigation. Depending on the
grade of regularization, contrast between a lesion and the sur-
rounding tissue could be underestimated. In addition, reduced
contrast arising from the blurred appearance of lesions in recon-
structed optical images generally limits the accuracy of the opti-
cal and functional parameters.
3.3.4 Reconstruction with prior knowledge
In multimodality optical breast imaging, the spatial information
from the high-resolution modality about tissue structure, in par-
ticular, lesion size and location, is used to improve the accuracy
of the optical and functional properties of breast lesions derived
from the optical data. In this sense, the optical method is used as
an adjunct modality that yields functional information about the
tissue not accessible by the other modality, whereas the detec-
tion of a lesion is based on the nonoptical method. The first step
in the analysis is the segmentation of the tissue into the lesion
and one or more background tissue types, such as fatty or glan-
dular tissue. Then, reconstruction can be performed either with
forcing the optical parameters in these regions to be uniform
(“hard prior”) or with a “soft prior” approach in which variations
of the parameters inside the regions and, in particular, changes
across the segmentation boundaries are permitted.
Originally, the hard prior approach was employed. The main
advantage of this method is that the number of unknowns in the
reconstruction is very small since each tissue type is described
by just one parameter vector of optical or functional properties.
On the other hand, this approach is very sensitive against errors
in the segmentation and deviations in contrast between the
imaging modalities. Ntziachristos et al. used the structural
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information from MRI to segment the tissue into the suspicious
lesion and a surrounding background. The optical properties of
the lesion were derived by first order perturbation theory using
the Rytov approximation of the diffusion equation.81
Brooksby et al.109 developed a soft prior reconstruction
scheme for combined optical and MR imaging with a spatially
varying regularization parameter linking the tissue properties of
healthy breasts to the reference properties of either adipose or
glandular tissue. As in the case of the pure optical measurements
at Dartmouth College, a spectrally constrained model based on
finite elements was employed for the reconstruction. In recent
work, a direct regularization approach was proposed and suc-
cessfully demonstrated on a patient with breast cancer that
no longer requires user-guided image segmentation.110
The information from digital mammographic tomosynthesis
in the multimodality instrument of the Massachusetts General
Hospital was exploited to generate a finite element mesh
accounting for the true shape of the breast. Reconstruction of
the functional parameters was then performed without prior dif-
ferentiation of tissue types [Fig. 4(e)]. The structural informa-
tion was finally applied to assign the reconstructed optical
and functional parameters to the different tissue types.84,88 In
early research, the application of different regularization
terms for the lesion and background tissue was discussed within
the linear Rytov approximation of the diffusion equation.111
Recently, a compositional approach was tested to analyze
data from healthy subjects whereby the tissue at each location
was assumed to be a mixture of adipose and glandular tissue.112
This method has then been extended to subjects with tumors.113
The ultrasound data from the combined near-infrared and
ultrasound instrument at University of Connecticut are used
to segment the tissue into the lesion and background tissue.
Then, a grid is defined with a fine voxel size in the lesion and
a coarse voxel size outside. Using this grid, the measured fre-
quency-domain data are modeled by a first-order Born approxi-
mation for diffuse reflectance in the semi-infinite medium.
Hereby, only changes in absorption are taken into account. The
total number of voxels corresponds roughly to the number of
measurements, and the inverse problem is solved without regu-
larization and without any further differentiation between the
lesion and the background voxels.114 In more recent work, theo-
retical and experimental attempts have been undertaken to
account for the influence of the chest wall that can strongly con-
tribute to the measured signals in the supine position.115
3.4 Broadband Spectroscopy
Most imagers display mammograms at a limited number of dis-
crete wavelengths, with a minimum of three wavelengths.
Operating at seven selected wavelengths (635 to 1060 nm) and
applying a perturbative approach for data analysis, it was pos-
sible to generate at each wavelength absorption difference Δμa
maps, with respect to the average absorption of the same breast.
From these data, corresponding concentration difference ΔC
maps for each tissue constituent (HbR, HbO2, water, lipid, and
collagen) with respect to the average concentration in the same
breast were deduced.86 As an example, in Fig. 5, the adipose
nature of the breast is apparent from the high lipid content in
the entire breast (in agreement with what was seen in the cor-
responding x-ray image). As expected based on physiology, the
residual of the mammary gland (upper quadrants), which causes
marked x-ray attenuation, is characterized by high content
of oxygenated blood, water, and also collagen. A blood vessel
is clearly detected in the maps of HbTandHbO2 content, similar
to the x-ray image. A carcinoma is characterized by strong
hemoglobin, water, and collagen absorption, as confirmed by
quantitative estimates in the reference area (see Fig. 5).
In contrast to imagers employing discrete wavelengths, the
handheld device developed at the University of California,
Irvine, exploits CW broadband operation with halogen lamp
illumination covering the range of 650 to 1000 nm together
with frequency-domain diode lasers at discrete wavelengths
(see Sec. 3.1).72,98 Tufts University has also recently developed
a scanning system that combines CW broadband Xenon arc
lamp illumination and detection with a CCD camera coupled
to a spectrograph. Spectral images of the compressed breast
are acquired every 8 nm between 650 and 950 nm.87 Although
only wavelengths shorter than 850 nm are exploited for data
analysis, thus excluding strong absorption peaks of major tissue
constituents, the spectral differences among tissue absorbers
proved significant enough to allow the estimate of oxy- and
deoxyhemoglobin, water, and lipid content.
Some breast studies (e.g., assessment of breast density) aim
at quantifying the average properties of breast tissue. Thus, they
may not require imaging capabilities. The set-up developed by
Lilge and coworkers belongs to the latter category.116 A halogen
lamp was used as a broadband light source, and light transmitted
through the compressed breast was collected coaxially and
detected by a spectrophotometer coupled to a 2-D CCD camera
to achieve continuous operation between 625 and 1060 nm with
3-nm resolution. Measurements were typically performed at
four positions on the compressed breast, thus providing some
information on breast heterogeneity. Principal component
analysis was widely applied to interpret the transmittance spec-
tra, showing that four principal components account for most of
tissue variability.116 Recently, a spectrally constrained global fit-
ting procedure based on photon diffusion has been introduced to
estimate the concentrations of HbO2, HbR, the percentage con-
tent of lipid and water.117
Fig. 5 Concentration difference maps ΔC of the main breast constitu-
ents (HbR, HbO2, HbT, lipid, water and collagen) of the craniocaudal
view of the left breast of a patient with a 25-mm invasive ductal car-
cinoma in the retroareolar area (compressed breast thickness
46 mm); x-ray image (top left) and reference image (bottom left)
show carcinoma (red arrow), and lesion area (black square) selected
to estimate lesion properties, respectively. The color bar range for ΔC
maps depends on the particular constituent, for details, see Quarto
et al.86 (Reprinted with permission of Optical Society of America
from Quarto et al.86)
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Another broadband system was also applied to investigate
breast tissue composition. It operated in the time domain, scan-
ning continuously between 610 and 1050 nm. A synchronously
pumped dye laser and an actively mode-locked Ti:Sapphire laser
provided picosecond pulses over the range of 610 to 700 nm and
700 to 1050 nm, respectively, and time-correlated single-photon
counting was used to detect the time distribution of either the
transmitted or the reflected signal.118 This was a complex
table–top laboratory set-up, not suitable for use in a clinical
environment. However, it allowed investigation of breast hetero-
geneity119,120 and changes in breast tissue with the menstrual
cycle,121 assessing HbT and StO2, water and lipid content, and
scattering properties. The scattering properties were also further
analyzed to estimate the equivalent size of the scattering centers
and the anisotropy factor g in the different experimental
conditions.
3.5 Diffuse Correlation Spectroscopy
DCS is a method to characterize blood flow in tissue, most likely
blood flow in the microvasculature.122 It measures fluctuations
in light intensity caused by the movement of scatterers like
RBCs. The method employs a near-infrared CW laser with
long coherence length to detect the intensity autocorrelation
function. The corresponding electric field autocorrelation func-
tion is then analyzed to derive a blood flow index. Although a
detailed microscopic model relating the drop in the field auto-
correlation function with correlation time is missing up to
now,123 changes in this index are taken as a quantitative measure
for changes in blood flow.122 The drop in the field autocorrela-
tion is best fitted to a Brownian motion model, rather than a
random flow model. Choe et al.124 used a two-fiber handheld
probe with a source–detector separation of 2.5 cm to perform
DCS measurements on breast tissue in reflection. This probe
was moved along a line crossing the lesion of interest. In a
study by Busch et al.,125 DCS was applied for measuring the
blood flow index in transmission through the breast, which
was strongly compressed similar to the conditions in x-ray
mammography.
4 Clinical Results
4.1 Detection and Characterization of Breast
Cancer
One of the fundamental questions of optical breast imaging is
how this technique can contribute to diagnosis and therapy
control of breast cancer, either as a stand-alone method or as
an adjunct modality to conventional imaging modalities. The
potential of the technique depends, in particular, on differences
in the optical and functional properties of healthy breast tissue
and of the various types of malignant and benign lesions.
Since optical and functional properties of breast tissue show
large intersubject variability, relative changes are of particular
interest.
First, exploratory studies with the various imaging devices
discussed in Sec. 3 had been conducted as case studies with
a small number of patients. Hereby, breast carcinomas were
found to show a large increase in HbT, whereas benign lesion
exhibited a smaller enhancement.81,126–129 When tissue blood
oxygen saturation StO2 was determined, a reduced value was
reported for carcinomas compared to normal breast tissue as
result of the initial studies.81,126–128 The first observation
corresponds to the increased vascularization of carcinomas
due to neoangiogenesis and circumferential growth. The
reduced oxygen saturation was interpreted as an indication of
a high metabolic rate in carcinomas. However, as will be dis-
cussed below in some detail, larger studies revealed that a con-
siderable number of breast tumors are characterized by an
increase in tissue blood oxygen saturation, i.e., vascular oxygen
supply may overcompensate transvascular oxygen loss and tis-
sue metabolic oxygen consumption.
Over the years, clinical results on a large number of subjects
have become available.47,72,86–88,130–133 Table 1 summarizes
cohort average values of functional properties for lesions and
healthy tissue that have been published by several research
groups. Table 2 lists results on tumor-to-normal tissue contrast
(given as relative values or differences), which represent aver-
ages of individual contrast values taken over the patient cohort
investigated. It has to be taken into account that instrumental
characteristics, methods of data analysis, and clinical protocols
differed significantly among studies. Thus, results obtained
from different studies are often difficult to compare quantita-
tively. Despite this caveat, more recent and extended studies
confirmed the expectation concluded from tumor neoangiogen-
esis that breast carcinomas have an increased content of hemo-
globin compared to host tissue. Average values of this increase
range from about 15%47 to 200%.134,135 In tendency, smaller val-
ues are typically obtained by the application of a homogeneous
model72,131 or by reconstruction,47,88,136 whereas heterogeneous
models yield larger ratios.86,134,135 The ratio HbTðTÞ∕HbTðNÞ
reflects large intersubject variability. Figure 6(a) gives an exam-
ple of the data spread from a study on 87 carcinomas analyzed
by a heterogeneous model.134 High intersubject variability was
also confirmed by Fang et al.,88 who detected statistically sig-
nificant difference in HbTwhen malignant lesions are compared
with healthy tissue in a paired test but not in an unpaired test.
Average data for benign lesions, such as fibroadenomas and
fibrocystic changes, show a smaller increase in HbT than
carcinomas86,133 or no significant differences at all.47 How-
ever, particular benign mastopathic alterations in the breast
can result in a large contrast in HbT images.138 In a study on
about 150 patients with suspicious lesions, only 40% of the his-
tologically confirmed carcinomas dominated the contrast in the
optical mammogram.85 In the other cases, either benign lesions
or highly vascularized tissue regions showed up with higher
contrast. Accordingly, the specificity of optical breast imaging
as a stand-alone imaging modality was found to be poor.52,69,85
The initial result that carcinomas generally exhibit lower tis-
sue blood oxygen saturation was not confirmed later by several
larger studies. The clinical studies performed during the
European OPTIMAMM project on optical mammography have
shown that, on average, tissue blood oxygen saturation StO2 in
breast carcinomas is not noticeably reduced.134,135 This observa-
tion has then been confirmed by studies of other groups.47,72,88
As illustrated by the data in Fig. 6(b), there are carcinomas with
StO2 above (StO2ðTÞ > StO2ðNÞ) and below (StO2ðTÞ < StO2ðNÞ)
normal. As discussed above, tissue blood oxygen saturation
reflects the balance between oxygen influx, i.e., oxygen supply,
and oxygen transvascular flux or tissue metabolic rate of oxygen
consumption, i.e., oxygen demand. This balance depends on
the tumor vascular network obtained by remodeling of the
host vascular network following vessel cooption, angiogene-
sis, circumferential growth, and regression of tumor vessels.
Breast tumors with tissue blood oxygenation above normal
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[StO2ðTÞ > StO2ðNÞ, see Fig. 6(b)] may be associated with high
tumor blood flow through large-diameter tumor blood vessels,
whereas breast tumors with StO2 below normal (StO2ðTÞ <
StO2ðNÞ) may indicate restricted perfusion at least in parts of
the tumor vasculature or high oxygen consumption in tumor tis-
sue. A plot of tumor blood oxygenation StO2ðTÞ versus total
hemoglobin concentration HbTðTÞ on a patient by patient
basis [see Fig. 5(a) of Ref. 134], corresponding to the data illus-
trated in Fig. 6, shows lower tumor blood oxygenation at smaller
total hemoglobin concentrations and StO2ðTÞ to approach an
upper limit at high total hemoglobin concentrations (HbTðTÞ).
This observation indicates that perfusion (rBF) and total hemo-
globin concentration (HbT), or vascular volume density (rBV),
are positively correlated. Similarly, a scatter plot of tumor to
normal oxygen saturation rStO2 ¼ StO2ðTÞ∕StOðNÞ versus
tumor to normal total hemoglobin concentration rHbT ¼
HbTðTÞ∕HbTðNÞ on a case by case basis reveals that tumors
with tissue blood oxygen saturation falling below normal are
associated with only small increases in total hemoglobin con-
centration, whereas tumors with StO2 above normal exhibit
larger increases in HbT.134,139 This spread in rStO2 shows
tumor-to-normal blood oxygen saturation obtained from diffuse
optical imaging to be unsuited for tumor versus normal
discrimination. Furthermore, conventional diffuse optical imag-
ing probes intravascular oxygen concentration, it does not
directly assess tissue partial oxygen pressure and hence cannot
detect tumor hypoxia. Saturation data for benign breast lesions
were found to be in the range of the values for healthy breast
tissue.47,86,88 Recently, a study on 26 breast cancer patients
employing CW spectroscopic imaging (650 to 850 nm) yielded
lower tissue blood oxygenation by ΔStO2∕StO2ðNÞ ¼ −5%.87
However, scattering was not measured for each patient sepa-
rately but was accounted for by using literature values both
for the reduced scattering coefficient at a reference wavelength
and for the scattering power to estimate the scattering spectrum,
raising doubts on the accuracy of the results obtained.
Statistically relevant data on water and lipid concentrations in
carcinomas were first published by Cerussi et al., who employed
a combined frequency domain and broadband spectroscopy sys-
tem, using, however, a smaller source–detector distance than
other groups. In this way, sufficient signal-to-noise-ratio could
be reached at wavelengths above 900 nm. Water concentration
was found to be larger in carcinomas, whereas lipid concentra-
tion was smaller in carcinomas than in normal tissue of the same
breast.72 Recently, Quarto et al. reported similar results obtained
from a parallel-plate breast scanner. Additionally, they reported
Table 1 Functional properties of malignant and benign breast lesions (N ¼ number of patients, FAD ¼ fibroadenoma) and of healthy breast tissue
from in vivo tissue optical spectroscopy.
Property References
Healthy Malignant Benign
Mean SD Mean SD N Mean SD N
HbT (μM) Grosenick et al.134 17.3 6.2 53 32 87
Spinelli et al.a 12.6 5.9 68.8 94.3 32
Cerussiet al.72 17.5 7.5 24.7 9.8 58
Zhu et al.130 — 71.9 18.8 61 39.1 14.9 114
Fang et al.88 19.2 6.5 27.2 13.9 26 24.3 12.3 17 (solid)
23.0 12.6 8 (cyst)
StO2 (%) Grosenick et al.
134 74 7 72 14 87
Spinelli et al.a 71.3 17.6 76.5 10.0 32
Cerussi et al.72 67.7 9.3 67.5 8.4 58
Fang et al.88 73 6 74.8 6.5 26 76.4 5.2 17
Water (%) Cerussi et al.72 18.7 10.3 25.9 13.5 58
Lipids (%) Cerussi et al.72 66.1 10.3 58.5 14.8 58
Scatter power b Grosenick et al.134 0.99 0.35 1.38 0.71 29
Spinelli et al.a 0.88 0.39 0.79 0.56 32
0.82 0.60 0.98 0.76 14 (FAD)
0.93 0.60 1.56 0.90 40 (cyst)
Cerussi et al.72 0.58 0.23 0.72 0.32 58
Fang et al.88 0.91 0.01
aReference 135 and P. Taroni (private communication).
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Table 2 Differences or ratios of functional properties between malignant or benign breast lesions (N ¼ number of patients) and healthy breast




Mean SD N Mean SD N
Hemoglobin Grosenick et al.134 rHbT 2.5 1.6 87
Cerussi et al.72 ΔHbR 4.62 μM 58
ΔHbO2 7.90 μM
Zhu et al.130 rHbT (malignant versus benign) (≈2) 61 114
Choe et al.47 rHbT 1.16 37 0.98 10
rHbR 1.18 1.11
rHbO2 1.14 0.94
Fang et al.88 rHbT 1.37 0.29 26 1.19 0.27 17 (solid)
1.06 0.17 8 (cyst)
Quarto et al.137 ΔHbR 5.15 μM 45 3.57 μM 38
ΔHbO2 5.76 μM 4.56 μM
Anderson et al.87 ΔHbT 2.4 0.4 μM
ΔHbR 1.2 0.2 μM
ΔHbO2 1.1 0.3 μM
StO2 Grosenick et al.
134 rStO2 (≈0.97)
Cerussi et al.72 rStO2 (≈1.0) 58
Choe et al.47 rStO2 0.98 37 0.96 10
Fang et al.88 rStO2 1.01 0.03 26 1.01 0.07 17
Anderson et al.87 ΔStO2 −5 1%
Water Cerussi et al.72 Δ% 13.3% 58
Quarto et al.137 Δ% 11.12% 45 9.95% 38
Anderson et al.87 Δ% 7 1%
Lipids Cerussi et al.72 Δ% −14.1% 58
Quarto et al.137 Δ% −15.57% 45 −10.95% 38
Anderson et al.87 Δ% −8 2%
Collagen Quarto et al.137 Δ% 58.25% 45 31.75% 38
μ 0s Grosenick et al.134 rμ 0s (785 nm) 1.2 0.4 87
Choe et al.47 rμ 0s (786 nm) 1.53 37 0.98 10
Fang et al.88 rμ 0s (830 nm) 1.18 0.34 26 1.07 0.14 17 (solid)
1.03 0.04 8 (cyst)
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corresponding data for benign lesions, showing the same quali-
tative trend but less marked differences than in the case of malig-
nant lesions with respect to normal tissue.86
In order to account for the increased Hb and water concen-
tration and for the decreased lipid concentration in a single
parameter, the following tissue optical index was proposed to





where HbR denotes tissue deoxyhemoglobin concentration. To
account for intersubject variability, Choe et al.47 adopted the
relative tumor-to-normal ratio rX of each measured parameter,
instead of its absolute value X. To discriminate malignant from
benign lesions, they proposed the optical index:
EQ-TARGET;temp:intralink-;e003;63;260 OI2 ¼
rHbT × rμ 0s
rStO2
; (3)
which relies on relative values and combines variables in agree-
ment with the expected tumor neoangiogenesis and higher tissue
cell density. However, according to the discussion given above,
relative tissue blood oxygenation rStO2 appearing in the denom-
inator may not improve discrimination.
In recent years, it is becoming more common to try not only
to detect optical contrast between breast lesions and healthy
tissue but also to correlate optically assessed macroscopic
parameters with microscopic information on tumors (e.g., grade,
proliferation), even though up to now this has often been
attempted only on small patient cohorts. Broadband CWacquis-
ition was performed by Anderson et al.87 on 26 breast cancer
patients. They observed significant correlation between the
optical contrast due to the different tumor-to-normal tissue
composition and the tumor grade as quantified by Nottingham
histologic score, which is a measure of tumor aggressiveness
and is used to guide therapy and predict its outcome. Water con-
tent showed the strongest correlation and HbT the weakest one.
Interestingly, no significant correlation was observed between
optically derived parameters and tumor size, which is expected
to increase optical contrast, as a homogeneous model was
used for data analysis.87 At the University of Pennsylvania,
Chung et al.140 investigated the correlation of optically estimated
blood parameters with the expression of Ki67 (proliferation
marker, N ¼ 18) and CD34 (angiogenesis marker, N ¼ 19).
Positive correlation was observed between StO2 and Ki67
expression (which is used to predict patient prognosis and
response to chemotherapy), and between HbT and mean
vessel area. At Dartmouth College, exploring optical tomogra-
phy for monitoring of NAC (see Sec. 4.4) in 11 subjects, sig-
nificant correlation was observed between pretreatment HbT
values and expression of CD105 (marker of tumor-induced
blood vessels) only in subjects that turned out to be responders
to therapy.141 These outcomes suggest that complex information
can be obtained noninvasively by optical means, and further
work is needed to understand it in depth and to fully exploit its
potential.
Several clinical studies have shown that, on average, the
reduced scattering coefficient of carcinomas is larger than that
of healthy tissue. Fang et al.88 and Grosenick et al.134 observed
an increase by about 20%, Choe et al.47 even by about 50%.
Higher scattering in malignant lesions than in benign lesions,
or healthy tissue, also agrees, at least qualitatively, with the
results of a small pilot study performed to compare optically
assessed scattering properties with the pathologic analysis of
microscopy images of cellular morphology.142 As shown in
Table 1, several groups have measured, in particular, higher scat-
ter power coefficients b in carcinomas than in healthy tissue.
Different results on the scattering properties of carcinomas
have been reported by Spinelli et al.,135 who observed a reduc-
tion of scatter power and also a slight reduction of μ 0s , possibly
indicating that the limits of perturbation theory used for data
analysis had been reached. For solid benign lesions, either no
significant change47,135 or a small increase of μ 0s was reported.
88
Recently, the concentration of collagen was considered as a
further parameter for the characterization of carcinomas and
benign lesions. Based on data from 62 patients with carcinomas
or benign lesions, Quarto et al.86 described a large increase of the
collagen concentration in carcinomas compared to a smaller
increase in benign lesions and supposed that collagen might
have high diagnostic relevance. Taking tissue absorption by col-
lagen into account reduces the total hemoglobin concentration
and increases StO2 since collagen contributes to tissue absorp-
tion not only above 900 nm but also below 700 nm.143
Choe et al.124 employed DCS to investigate the microvascu-
lar blood flow of healthy tissue and malignant breast lesions.
Results on 32 subjects revealed on average a 2.25-fold larger
blood flow index for malignant lesions compared to normal tis-
sue of the same breast. Similar results were obtained when
the contralateral breast was used as reference, which implies
that malignant tumors have significantly higher blood flow than
normal tissue.
Several papers discussed optical properties of (liquid filled)
cysts. These lesions could be distinguished from carcinomas and
solid benign lesions by their smaller reduced scattering
coefficient.85,135,144 By contrast, Fang et al.88 did not see such a
Fig. 6 (a) Total hemoglobin concentration and (b) oxygen saturation
of 87 carcinomas plotted versus the corresponding reference value of
healthy tissue of the same breast (from Grosenick et al.134).
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reduction. Instead, these authors reported a significantly reduced
StO2 value in cysts as compared to healthy tissue and to other
lesions.
Statistical tests performed on the discussed composition and
functional properties of carcinomas, healthy tissue and benign
lesions revealed significant differences leading to the conclusion
that these properties are suited to diagnose carcinomas and to
differentiate between malignant and benign lesions, different
from what was suggested by earlier studies.52,69,85 Accordingly,
high sensitivity and specificity values for optical imaging were
obtained: e.g., when HbT is used as criterion for diagnosis, Choe
et al.47 reported a sensitivity of 98% and a specificity of 90% and
Zhu et al.130 obtained a sensitivity of 92% and a specificity of
93%. Chance et al.74 detected 44 carcinomas from 116 subjects
with a sensitivity of 96% and a specificity of 93% by using HbT
and StO2. However, the latter results should be taken with cau-
tion since only CW radiation at three different wavelengths was
used and separation of absorption from scattering thus was
difficult. Also, Deng et al.113, exploiting data fusion on x-ray
imaging and optical tomography to build HbT maps, were
able to differentiate 30 malignant from 24 solid benign lesions
(p ¼ 0.006 in a two-sample t-test). For the discrimination
between 16 malignant and 9 benign lesions, Zhao et al.145 tested





which were obtained from MRI-guided diffuse optical tomog-
raphy. They achieved an area under the curve (AUC) of 0.79
and 0.94, respectively, suggesting that by additionally taking
into account, tissue composition besides total hemoglobin
can improve the diagnostic potential. Mastanduno et al.146 ana-
lyzed 30 patients from the same study and reported an increase
in specificity from 67% for MRI to 89% when results from MRI
and TOI3 are combined. Along this line, Kukreti et al.
147
exploited the system developed at the University of California,
Irvine, to investigate spectral differences between malignant,
benign, and healthy breast tissue over a broad spectral range.
This allowed them to identify minute (ppm) spectral signatures
observed in malignant tissue that cannot be accounted for by
hemoglobin, water, and lipids. Exploiting this “specific tumor
component,” they were able to discriminate between malignant
(N ¼ 22) and benign (fibroadenomas, N ¼ 18) lesions with
sensitivity of 91% and specificity of 94%. However, to our
knowledge, this approach has not been followed any further.
When interpreting the high values of sensitivity and specific-
ity reported, one should have in mind that they were in part
derived by exploiting prior knowledge about the existence
and even the location of the lesion. The task of optical imaging
focuses on determining functional parameters for tissue regions
defined by other modalities. This approach differs from the
original attempts of optical mammography that aimed at the
detection of lesions from the optical image itself and that
revealed a low specificity of the optical method.52,55,131,148 With
lesion position known from a conventional breast imaging
modality, tissue regions with high contrast in optical mammo-
grams that do not coincide with the position of the known lesion
in the conventional modality are ignored. This approach avoids,
in particular, the problem of low specificity and yields values
above 90%.
Generally, the high values for sensitivity and specificity are
encouraging to use optical imaging as an adjunct modality to
conventional breast imaging. The various clinical studies
have shown that HbT, water, lipid and collagen concentration,
the scattering properties, and related parameter combinations
can potentially be exploited to improve the workflow in breast
cancer diagnosis.
4.2 Dynamic Response to External Impact
The work on the detection and differentiation of breast tumors
discussed so far was related to properties of breast tissue
under static conditions. There have been several attempts to
induce dynamic changes of the intrinsic functional properties
in order to discriminate malignant from benign lesions and from
healthy breast tissue. With respect to the origin of the optical
contrast, one can distinguish between (1) alterations that pri-
marily vary blood volume and blood flow and (2) alterations
that primarily affect blood oxygen saturation. Due to their dis-
organized vasculature and the particular metabolism of cancer
cells, carcinomas should show a different transient response
with respect to healthy tissue and possibly to benign alterations.
Schmitz et al.66 proposed a Valsalva maneuver, which was
expected to temporarily increase the Hb concentration in the
breast due to vein congestion. Using their dynamic dual-breast
imager, a single case study revealed a significantly slower recov-
ery of the reconstructed HbR concentration after the end of the
breath hold for a carcinoma compared to the contralateral
healthy breast. More recently, measurements on two patients
with carcinomas using a novel instrument confirmed the slug-
gish recovery that reflects the increased resistance of the tumor
vasculature to blood flow.149
Blood volume and blood flow can also be varied by the appli-
cation of external pressure to the breast. The parallel-plate
instrument ComfortScan of DOBI Medical International Inc.
temporarily applies a pressure of 10 mm Hg to the breast tissue
in order to affect cessation of blood flow in the abnormal capil-
laries of malignant tumors. The local trapping of RBCs is
expected to cause a fast reduction of StO2 compared to healthy
tissue and benign lesions, where blood flow is still going on.
Such a reduction is observable by a reduction of light transmis-
sion around 640 nm. A multicenter clinical trial revealed 74%
sensitivity and 92% specificity.150 In a recent study, a sensitivity
and specificity of 80% and 87% were obtained, respectively.151
Furthermore, a study on 617 young women showed a sensitivity
of 98% and a specificity of 87%.152 The applied pressure of only
10 mmHg should be compared to the elevated interstitial pres-
sure in breast carcinomas known to rise up to 30 mmHg or even
higher.13
Xu et al. used a handheld probe with CW light sources and an
integrated load sensor to temporarily increase the pressure on
top of a lesion known from ultrasound for 10 s. However, mea-
surements on 36 cases did not reveal any significant decrease in
StO2 originating from the pressure change.
153
A temporal change in blood oxygen saturation can be
induced by changing either the oxygen or the carbon dioxide
(CO2) concentration in the inhaled gas. Enhanced oxygen inha-
lation results in a global increase of StO2, which then causes
vasoconstriction. Enhanced CO2 leads to a right shift of the
oxy-Hb dissociation curve corresponding to a decrease in
StO2, which finally results in vasodilation. Carpenter et al.
used these effects in a pilot study on two patients with carcino-
mas. The patients received inhalation gas during four cycles,
each cycle corresponding to 2 min 100% O2 supply followed
by 2 min of carbogen gas (95%O2, 5% CO2). Using MR-guided
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optical imaging, normal tissue showed a stronger modulation
between decreased HbT due to vasoconstriction and enhanced
HbT due to vasodilation than the carcinomas. This difference
was probably an indicator for the lack of adequate response of
smooth muscle cells in the carcinoma vessels required for adapt-
ing the vessel diameters. Furthermore, strong temporal delays
between the vessel diameter modulation in the healthy and
the tumor tissue were observed.154 Using a CW transillumina-
tion method, Dixit et al.155 investigated patients with malignant
and benign breast lesions, who were inhaling carbogen. How-
ever, the results on temporal changes in HbO2 and HbR for the
various lesions derived by an eigenvector approach did not
clearly show common features of the lesions. A general increase
in oxygenation visible in healthy as well as diseased subjects
was explained by the increased oxygen content in carbogen
compared to air. The difficulties of Dixit et al. to observe a
robust hemodynamic response by using carbogen are in line
with a study on healthy subjects by Carpenter et al.,156 who
reported that air/carbogen as well as air/oxygen breathing yield
less robust data than the oxygen/carbogen modulation method.
The effects of pressure-induced changes in breast tissue were
also investigated in a number of studies, on healthy subjects,
mainly, to understand changes in the tissue functional parame-
ters by compression plates or pressure-induced optode coupling
to tissue. In a first study on five healthy subjects, Jiang et al.157
reported that the pressure of a circular optode arrangement on
the tissue results in an increase of HbT and StO2 and in
a decrease of the tissue water content. By contrast, a later
study of this group on 17 healthy subjects revealed a decrease
of HbT and no significant alterations in StO2 and water
concentration.158 Similar to the latter result, Carp et al. observed
a decrease in HbT when using high compression in their paral-
lel-plate combined optical and x-ray approach. Moreover, a
decrease in StO2 and μ 0s was observed.
159,160 The reduced HbT
indicates that due to higher pressure blood is partly pressed out
of the breast vasculature. Furthermore, for high compression
similar to x-ray mammography, a strong reduction in blood
flow of about 88% was observed using DCS measurements.125
Altogether, these results indicate that tissue compression could
reduce optical imaging contrast hampering the detection of
tumors. Busch et al.125 report on a noticeable effect of soft tissue
compression. On the other hand, results on tumor contrast
obtained with soft tissue compression did not noticeably differ
from data obtained with pressure-free techniques. This is also
the case for dynamic measurements using a bolus of ICG
(cf. next section).
4.3 Exogeneous Contrast Agents and Fluorescence
Mammography
The results on endogeneous tissue contrast discussed in
Secs. 4.1 and 4.2 show several promising features that could
be helpful in breast cancer diagnosis. However, they did not
yet reveal sufficient potential to substantially change the clinical
workflow in diagnostic mammography. Exogeneous contrast
agents offer the possibility to exploit contrast mechanisms that
are superior to endogeneous tissue contrast and, therefore, could
help to improve cancer detection and differentiation. In particu-
lar, molecular imaging has been discussed and investigated for
the past decade as a new way for early detection of tumors with
high specificity.
However, the development and approval of a new dye suited
for applications on human subjects is a long and expensive
process. So far, two contrast agents have been applied in optical
imaging studies on patients with breast cancer. The first one is
the well-known NIR dye ICG, which is routinely used in clinical
practice for other applications (e.g., hepatic function and ocular
fundus fluorescence angiography) since many years. ICG has
been approved by regulatory agencies for investigation of the
microcirculation yet has not been approved for fluorescence
imaging of the breast. The second dye is a newly developed sub-
stance with the name omocianine, which does not have any
approval for medical applications so far.
ICG can be detected in the breast by its absorption around
760 nm as well as by its fluorescence around 830 nm. The phar-
macokinetic behavior is well known. After intravenous injec-
tion, ICG quickly binds to high molecular weight plasma
molecules like lipoproteins. Within typically less than 10 min,
the dye is cleared from the blood by the liver.
A first application of this dye in optical mammography was
reported by Ntziachristos et al.,80 who reconstructed the change
in absorption observable about 3 min after intravenous injection
of a bolus of ICG. Optical imaging was restricted to a tissue slice
selected from concurrent Gd-enhanced MRI taken in the same
parallel-plate geometry as the optical imaging. Investigations on
two subjects with a malignant (1-cm invasive ductal carcinoma)
and a benign (1.5 cm fibroadenoma) lesion showed good spatial
correlation of high ICG absorption with the Gd enhancement
visible for both lesions. Outside the lesions, areas with smaller
ICG enhancement were visible, similar to moderate enhance-
ment obtained for the healthy case. The possible benefit of
the ICG enhanced absorption with respect to the measured
intrinsic lesion absorption was not considered by the authors.
Intes et al.161 measured the full-time course of ICG uptake
and washout on three patients using a single-wavelength CW
imager. The circular arrangement of sources and detectors on the
freely pending breast was positioned according to the expected
lesion position determined from palpation. Figure 7(a) displays
the time courses obtained from reconstruction of absorption
changes using a perturbation approach. The two malignant cases
show a significantly slower inflow and wash-out in comparison
to the benign lesion and to the surrounding normal tissue. This
slower inflow and wash-out likely indicated the increased resis-
tance to blood flow arising from the chaotic vessel structure in
the carcinomas, and possibly indicated extravasation of ICG.161
Rinneberg et al.85 used the first generation PTB parallel-plate
optical mammograph to investigate the time course of ICG
absorption after bolus injection for 11 patients with suspicious
lesions. These measurements showed distinct patient-to-patient
variations of the wash-out curves. However, the temporal char-
acteristic for the carcinoma and healthy tissue of the same breast
was almost identical in all cases. As an example, Fig. 7(b) shows
the time courses for a 2-cm invasive ductal carcinoma and for
two reference positions within the surrounding normal tissue,
chosen on different sides of the tumor. In each case, ICG absorp-
tion has been normalized to the HbT value measured at the same
location of the breast. Since the three curves fall on top of each
other after normalization, ICG absorption is proportional to
absorption by hemoglobin. This observation reflects the
known strong binding of ICG to blood plasma proteins, which
hinders extravasation of the dye molecules. The authors con-
cluded that the investigation with ICG yields essentially the
same tumor absorption contrast as accessible from the intrinsic
total hemoglobin concentration.
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In 2007, Corlu et al.60 demonstrated that ICG can be detected
in breast cancer by fluorescence measurements. The investiga-
tions were performed with the frequency-domain/CW parallel-
plate instrument of the University of Pennsylvania equipped
with spectral filters for fluorescence detection by the installed
CCD camera. Fluorescence data were acquired in a time window
from 6 to about 16 min after injection of the ICG bolus. Images
of the ICG concentration at 10.2 min after ICG injection and of
other functional parameters, such as HbT, StO2, and μ 0s were
derived by 3-D reconstruction. Data on three patients with inva-
sive ductal carcinomas revealed a lesion-to-background contrast
in the reconstructed ICG concentration of 4∶1 to 6∶1 compared
to about 1.3∶1 contrast in HbT and typically, 1.5∶1 contrast in
μ 0s . The strong difference in the ICG and HbT concentration con-
trast was discussed as an indicator for extravasation of ICG due
to leaky tumor vasculature.60 This result disagrees with the data
of Rinneberg et al. displayed in Fig. 7(b), which exhibits similar
contrast for ICG and HbT about 10 min after bolus injection.
As discussed above, extravasation was negligible within the
considered 10-min time window after bolus injection for the
11 cases investigated in this study.85
In 2009, first results of a clinical study with the PTB fluo-
rescence mammograph were published in which extravasation
of ICG in carcinomas was explicitly exploited as contrast
mechanism.162 This study differed in two main aspects from
all previous investigations discussed above. First, the ICG con-
centration was not only measured during the washout period but
also, at a later time at which no more ICG could be seen circu-
lating through the blood vessels. Second, the ICG bolus was
followed by a typically 20 min lasting period of constant
ICG infusion. The aim of this infusion was twofold. It should
allow for a measurement at constant ICG concentration in the
vascular compartment during infusion to avoid difficulties aris-
ing from the continuous drop of the ICG concentration follow-
ing a bolus injection during image acquisitions times of several
minutes. Furthermore, ICG infusion over an extended period of
time should increase ICG extravasation compared to the appli-
cation of a bolus followed by rapid ICG clearance from blood by
the liver. Figure 8 illustrates the results obtained at different
times of the investigation for a patient with an invasive carci-
noma. The mammogram in Fig. 8(a) shows the late-gate inten-
sity absorption contrast at 660 nm before injection of the dye,
Fig. 8(b) shows the ICG fluorescence signal that was measured
during the infusion period, and Fig. 8(c) shows the ICG fluo-
rescence signal recorded about 25 min after the infusion had
been stopped.
The first two images exhibit essentially the same structures in
the breast. In Fig. 8(a), the carcinoma as well as several blood
vessels are visible due to the corresponding hemoglobin absorp-
tion (at 660 nm mainly deoxy-Hb), and in Fig. 8(b), the same
structures are visible from fluorescence since the ICG is con-
tained almost entirely in the vasculature inside and outside the
carcinoma. The situation changes dramatically in Fig. 8(c).
Now, the ICG from the vessels has been washed out completely,
and the small amount of ICG that extravasated through the leaky
vessel walls of the carcinoma becomes visible. A study on
20 patients showed that ICG extravasation occurs only for
malignant and not for benign tumors.163 This result is in accor-
dance with the EPR effect of macromolecules in solid
Fig. 8 Optical mammograms of a patient with an invasive ductal
carcinoma (arrow) from the study of Hagen et al.:162 (a) absorption
(normalized late-gate intensity) at 660 nm without contrast agent,
(b) ICG fluorescence during dye infusion, and (c) ICG fluorescence
after washout of the dye from the vessels.
Fig. 7 (a) ICG inflow and washout characteristics after bolus injection
for three patients with breast tumors measured by Intes et al.;161 case
I: fibroadenoma (diameter 1 to 2 cm), case II: adenocarcinoma (diam-
eter 2 to 3 cm), case III: invasive ductal carcinoma (size 4 cm × 3 cm)
(reprinted with permission of American Association of Physicists in
Medicine from Intes et al.161); (b) time courses of ICG absorption
after bolus injection normalized to HbT for a 2-cm invasive ductal car-
cinoma and two healthy reference locations measured by Rinneberg
et al.85
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carcinomas. ICG, which strongly binds to the lipoproteins in the
blood, acts as a fluorescent label for these macromolecules.
Such macromolecules can extravasate in carcinomas due to
the leakiness of the vessels and remain there for an extended
period of time. Interstitial flow is reduced due to the impaired
lymphatic system. By contrast, the vasculature in the benign
lesion was not permeable for the ICG-labeled macromolecules.
Hence, fluorescence mammography with ICG offers a way to
differentiate malignant from benign lesions in the breast,
which is a clear advantage compared to measurements exploit-
ing the intrinsic tissue contrast only.
The dye omocianine mentioned above, also known under the
name tetrasulfonated carbocyanine dye, does not show strong
binding to blood plasma proteins.164 This contrast agent circu-
lates more than 24 h through blood vessels.64 So far, it was used
in two dose finding studies. Investigations on 52 patients were
performed in a multicenter study with a prototype CW fluores-
cence mammograph from Imaging Diagnostic Systems, Inc. (Ft.
Lauderdale, United States).165 This study revealed considerable
variations in sensitivity at different omocianine concentrations.
At the dose optimum, a detection rate of 100% was found for
malignant lesions, whereby a large number of additionally
visible lesions indicated low specificity. Van de Ven et al.64
reported on a study with omocianine performed with the Philips
fluorescence mammograph. Dye enhancement was observed in
lesions as well as in glandular tissue and at the nipple, which
indicates problems with differentiation of lesions from healthy
tissue, too.
Compared to these results, fluorescence mammography with
ICG seems to offer a higher potential for the differentiation of
malignant and benign lesions. ICG fluorescence mammograms
recorded during the extravascular phase are superior to the
intrinsic tissue contrast because (1) carcinomas are visible with-
out background contrast from blood vessels and (2) benign
lesions do not show contrast despite enhanced hemoglobin con-
centration. So far, these results are based on a small number of
cases only, and further studies are required to obtain a sufficient
data base for evaluating tumor detection and differentiation
based on the EPR effect.
4.4 Monitoring Patient Response to Neoadjuvant
Chemotherapy
The capability of near-infrared spectroscopy to measure func-
tional parameters of carcinomas at known locations within
the breast has led to its application for monitoring the response
to NAC. This therapy is increasingly used for patients with
locally advanced breast cancer to shrink tumor size prior to
surgery. NAC has been shown to increase the rate of breast-
conserving surgery.166 Moreover, patients with a pathological
complete response to chemotherapy are associated with longer
disease-free and overall survival.167 It is desirable to predict the
likely success of NAC as early as possible, preferentially before
or right after its start. For this purpose, functional imaging meth-
ods seem to be better suited than morphological imaging
techniques.168 Compared to techniques like dynamic contrast-
enhanced MRI or PET mammography, NIR spectroscopy is
technically less demanding and does not need a contrast agent.
The first application of optical imaging for NAC treatment
monitoring was demonstrated at the University of California,
Irvine.169 Meanwhile, several of the instruments discussed in
Sec. 3 have been employed in corresponding clinical studies
including multimodality imagers. Using the DOSI instrument,
Cerussi et al.170 found that for a 3-month NAC treatment with
adriamycin/cytoxan, pathologic complete responders and non-
responders could be distinguished already after the first week
of the therapy. At this time point, deoxy-Hb concentration and
water concentration had dropped by 27% 15% and 11%
15%, respectively, for responders, whereas nonresponders did
not show any significant changes in these parameters. The dif-
ferentiation between responders and nonresponders was also
obtained when the reduction of HbT was considered instead.
Furthermore, the responder group showed a significantly larger
tumor-to-normal ratio of oxy-Hb than the nonresponders before
NAC. In other words, the carcinomas in the nonresponder group
should originally have had a lower StO2 value compared to the
responders. This assumption was then confirmed in a later paper,
where a pretreatment StO2 threshold value of 76.7% was found
between the two groups.171 Another study with the DOSI instru-
ment revealed that pathologic complete responders and partial
responders could already be distinguished from nonresponders
1 day after start of the NAC by a characteristic flare in the tumor
oxy-Hb concentration. On average, this increase in the responder
group amounted to more than 40% of the baseline value.168
These investigations caught the interest of a number of
groups involved in breast tissue optical spectroscopy. As dis-
cussed above, the objective is to discriminate responders from
nonresponders as early as possible, ideally before or shortly
after the start of chemotherapy. Soliman et al. proposed to con-
sider the amount of deoxy-Hb and the water volume instead of
the deoxy-Hb concentration and the water volume fraction
when investigating patients that obtained different NAC treat-
ments.172,173 By taking these quantities for the entire breast, not
only for the lesion volume, a differentiation between responders
and nonresponders was obtained after the first week of treat-
ment. At this time point, an increase of both quantities was
observed for responders, whereas nonresponders showed a
decrease. Four weeks after the start of the treatment, separation
worked best for the amount of deoxy-Hb in the lesion and not in
the whole breast. The investigations were performed with a
commercial instrument (SoftScan from ART, Canada) that
provides hemoglobin concentration, fractional water volume,
lipid fraction as well as scatter power and scatter amplitude val-
ues from measurements at four wavelengths between 690 and
830 nm.173
A clinical study with the combined optical and ultrasound
handheld probe of the University of Connecticut showed for
the first time that responders and nonresponders to NAC are
characterized by differences in the pretreatment tumor hemoglo-
bin level. Pathologic complete and near-complete responders
exhibited significantly higher tumor concentrations in HbT
(75.7 18.8 μM) as well as in oxy- and deoxy-Hb than subjects
with modest or no response (tumor average HbT of 51
14 μM).174 Recently, Zhu et al.175 proposed a prediction model
for NAC response combining HbT concentrations with conven-
tional pathologic tumor parameters. Unlike Zhu et al., who uti-
lized absolute values of HbT concentrations, Jiang et al.176
considered relative baseline values of pretreatment tumor HbT
with respect to the contralateral breast. In a clinical study on 19
patients with the combined MR-optical instrument developed at
Dartmouth College, these relative values were found to be sig-
nificantly different between responders and nonresponders.
Perfect differentiation was obtained when the percent change
in tumor HbT within the first cycle of treatment was taken as
criterion, which was similar to a previous observation on seven
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patients.177 In an exploratory single case study, NIR spectros-
copy was performed together with DCS using a handheld probe.
Hereby, the tumor-to-normal blood flow contrast was signifi-
cantly increased on day 3 and significantly decreased on day
5 after start of treatment.178 Recently, investigations have been
started with the dynamic dual breast imager developed by NIRx
Technologies. Two weeks after start of the NAC, pathological
complete responders showed a faster recovery of deoxy-Hb
after a short breath hold than partial and nonresponders.179
Several studies discussed the time-dependent change of the
tumor functional properties over different treatment cycles, in
part until the end of NAC.141,169,172,173,180–182 Pakalniskis
et al.141 reported that tumor HbT decreases significantly during
NAC for pathologic complete responders and not for partial
responders. A similar trend is visible in the long-term tumor
data of Falou et al.172,173 Schaafsma et al.182 focused on the
investigation of patients with HER2-negative breast cancer,
which is associated with decreased angiogenesis resulting in
less pronounced differences in HbT between tumor and healthy
tissue. The 18 responders in this study showed a statistically
significant decrease in oxy-Hb concentration already after the
first treatment cycle compared to the four nonresponders.
The predictive value for differentiating responders and nonres-
ponders was comparable to DCE-MRI based measurements of
tumor volume carried out after the third of six treatment cycles
and appeared to outperform DCE-MRI evaluation according to
the response evaluation criteria of solid tumors guidelines.182
The various investigations have shown that optical imaging is
a well suited tool for monitoring the progress during NAC.
Functional parameters are highly correlated to the patient’s
response to treatment. In this scenario, the location of the
tumor is known and the original size of the tumor is large, which
enables one to determine the functional parameters with high
signal-to-noise ratio. On the other hand, there are still many
differences in the investigated types of NAC, in patient groups,
in measurement protocols, data registration, and analysis that all
together hamper the comparison of the results obtained. In par-
ticular, different approaches were used to determine the numbers
of responders and nonresponders from pathological assessment.
Generally, subjects can be divided into pathologic complete
responders, partial responders, and nonresponders. Hereby,
complete response is typically defined as microscopic evidence
that invasive cancer cells had entirely disappeared. In some stud-
ies, subjects with a reduction in tumor size of at least 50% were
considered as partial responders, otherwise as nonresponders.168
In other studies, classification of partial responders and nonres-
ponders was based on grading of tumor cellularity.174,182 In part,
the size criteria was combined with the additional demand of a
significant decrease in tumor cellularity to classify a subject as
(partial) responder.172,173 The different ways of pathological
classification can have considerable influence on the evaluation
of the optical monitoring method, e.g., Cerussi et al.170 men-
tioned explicitly that their number of responders differed when
using either a binary or a tertiary pathologic classification
scheme. Furthermore, since a pathological complete response
is accepted as important prognostic factor, some investigators
evaluated NIR monitoring of NAC by considering only patho-
logic complete responders as true responders, whereas partial
responders and nonresponders were combined in the overall
nonresponder group. Other investigators took complete and par-
tial responders into the same group and the remaining nonres-
ponders as the alternative group.
This variety of approaches emphasizes the need for improved
consensus, and that care has to be taken when comparing results
from various studies available. Furthermore, to achieve clinical
translation, joint efforts should be undertaken to impressively
demonstrate the advantages of the optical monitoring technique
as a contribution to personalized treatment of patients. A first
step into this direction is the multicenter clinical trial of DOSI
instruments, recently started at five clinical sites.183 It remains to
be seen how early and how reliable breast tissue optical spec-
troscopy can predict the outcome of NAC, preferentially even
for pretreated subjects, with clear potential benefits for patients
and cost reduction for the healthcare systems.
4.5 Assessment of Breast Density and Estimate of
Cancer Risk
Breast density is a measure of the extent of radiodense fibrogland-
ular tissue in the breast.184 It reflects composition in terms of fat,
stromal, and epithelial tissues. As implied by its definition, it is
assessed either from the qualitative or quantitative analysis of x-
ray mammograms. In the former case, which is still most common
in clinical practice, x-ray mammograms are visually inspected by
an expert radiologist, and breast density is most often classified
through BI-RADS categories:184 (1) almost entirely fat; (2) scat-
tered fibroglandular densities; (3) heterogeneously dense; and
(4) extremely dense. However, the quantitative estimate of breast
density is becoming more and more widespread. It is performed
analyzing x-ray mammograms with dedicated percentage of dense
(fibroglandular) tissue present in the breast.
The importance of the assessment of breast density comes
from its identification as a risk factor. Over the years, a large
number of studies have investigated breast density, and it is
now widely recognized that it is a strong independent risk factor
for developing breast cancer. Actually, it is the strongest risk
factor, apart from gender and age: it has been observed that risk
is two to six times higher in women with dense breasts (BI-
RADS category 4) than in women with fatty breasts (BI-RADS
category 1).185 High density also increases significantly the risk
of cancer recurrence.186
The information on breast density can be useful to identify
women that are at high risk and deserve personalized screening/
diagnostic paths. Moreover, different from other risk factors,
breast density can be modified. Thus, its estimate can help mon-
itoring the effects of interventions that aim at reducing breast
density and the related risk. Actually, not only the preventive
administration of chemotherapy drugs can reduce breast density
but also nonpharmaceutical interventions, like changes in the
diet or lifestyle.187,188 Breast density can also be exploited as
an intermediate endpoint in studies on breast cancer etiology.
Finally, information on breast density has recently proved useful
to predict the pathologic response to neoadjuvant chemo-189 or
endocrine therapy.190
As mentioned above, x-ray mammography is the gold stan-
dard for the assessment of breast density and the method that is
generally applied in clinical practice. This implies that the infor-
mation on breast density becomes known only at the time of the
first mammography, typically at the age of 50.191 On the con-
trary, both for monitoring women at high risk and for devising
actions to reduce breast density, it would be beneficial to know it
earlier in life. MRI has effectively been applied to estimate the
amounts of fibroglandular and fat tissue.192,193 However, high
costs, long measurement times, and, in some cases, limited
patient acceptance make MRI unsuitable for screening wide
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populations. The sensitivity of optical techniques to tissue com-
position and their general features (relatively inexpensive and
simple to operate, well accepted, generating absolute, opera-
tor-independent results) makes them potentially interesting can-
didates as alternative means for the estimate of breast density.
Starting a decade ago, this possibility has been extensively
investigated by Lilge and coworkers in Toronto.116,194 In particu-
lar, they have been performing CW transmittance spectroscopy
over a broad spectral range (625 to 1060 nm) at four positions
(central, medial, distal, and lateral) on both breasts and interpreting
transmittance data with principal component analysis. The prin-
cipal components reflect variations in tissue attenuation (due to
both absorption and scattering properties) and, thus, contain
information on tissue composition and density. Each spectrum
is a weighted average of component spectra, each weighted by a
score. Four principal components proved to account for almost
the entire tissue variability. Collecting data on more than 200
volunteers, they have shown good correlation between the
four scores and percentage mammographic density (assessed
using Cumulus,195 a computer-assisted thresholding software
for the analysis of x-ray mammograms).194
At Politecnico di Milano, we have applied time-resolved dif-
fuse optical imaging performed at seven wavelengths (635 to
1060 nm) to estimate breast tissue composition and structure
of 2018 subjects. In particular, time-domain operation in a wave-
length range extending beyond 900 nm allowed not only the
assessment of blood parameters (total hemoglobin content
and oxygenation level), as typically performed by optical instru-
ments, but also of tissue composition in terms of water, lipid,
and collagen. The scattering parameters (amplitude a, i.e., scat-
tering at 600 nm, and power b) were also estimated. The results
confirmed strong positive correlation with optically derived
water content (and corresponding negative correlation with lipid
content), as expected, considering that water strongly absorbs x-
rays, while adipose tissue is essentially translucent to x-rays. An
optical index based on tissue composition and structure proved
suitable to classify noninvasively breast density in agreement with
BI-RADS classification performed by an expert radiologist.196
Even more interesting, collagen content and scattering slope b
increased progressively and significantly with breast density.196
Some other limited studies also confirmed the positive correlation
between scattering parameters and mammographic density.197–199
The scattering properties, especially the scattering power, are
expected to depend on collagen structure in tissue. So, the com-
bination of collagen content and scattering parameters may be
used to obtain more comprehensive information on collagen in
breast tissue. Collagen is a protein family and a major constituent
of connective tissue. Fibrillar collagens are essential in determin-
ing stromal architecture [see Figs. 1(b) and 2(b)]. Morphological
alterations that can be attributed to changes in collagen content
and structure occur in breast stroma not just during invasive tumor
growth but also in the preneoplastic phase: alterations of stromal
architecture and composition are a well-known aspect of both
benign and malignant pathologies, and may play an initial role
in breast carcinogenesis.200–202 The optical assessment of collagen
content (and potentially also of collagen structure through scat-
tering parameters) may prove of great interest for the assessment
of cancer risk, which is associated to mammographic density.
Based on what has been discussed above on the link between
collagen and cancer development, it might provide noninvasively
a more direct estimate of risk than x-ray mammography, which is
more sensitive to water content than to collagen. Recently, very
preliminary data have also suggested that collagen might provide
independent information on risk with respect to mammographic
density.203 If confirmed, this hypothesis would further increase
the interest in optical means for the estimate of cancer risk.
4.6 Dependence of Breast Tissue Composition and
Structure on Demographic Parameters
Two recent works on the estimate of breast density (see Sec. 4.5)
have applied broadband117 or multiple-wavelength204 acquisi-
tion over an extended spectral range (650 to 1000 nm or
wider) on more than 200 subjects. Blackmore et al.117 studied
how blood parameters (HbT and StO2), water and lipid content,
and scattering parameters (amplitude and slope) vary with age
and body mass index (BMI) in pre- and postmenopausal
women. Taroni et al.204 estimated tissue composition (water,
lipids, and collagen), functional information (blood parameters
HbT and StO2), and information on the microscopic structure of
tissue (scattering amplitude a, i.e., scattering coefficient at
600 nm, and power b), investigating the correlation with age,
BMI, menopausal status, and use of oral contraceptives. Both
studies highlighted how age, BMI, and menopause affect tissue
composition, increasing the weight of the adipose fraction at the
expense of the fibroglandular fraction. This corresponds to sig-
nificant decrease in water and collagen content and correspond-
ing increase in lipid content. The total hemoglobin content also
decreases, while the trend for oxygen saturation is less clear.
The use of oral contraceptives seems to have opposite effect,
corresponding to an increase in the fibroglandular tissue fraction.
After age adjustment, the trend is the same, but the difference
between users of oral contraceptives and nonusers are no longer
statistically significant or only close to significance. However, it
should be taken into account that complete information (e.g.,
duration of use) was missing for several subjects, thus further
studies are needed to draw definite conclusions. In particular, data
referring to the effects of the menopausal status are reported in
Table 3. In one case, tissue composition is estimated as relative
percentage values and in the other one as absolute concentrations.
However, the trends with menopause are very similar for all mea-
sured parameters, except for the scattering power, which showed
a significant decrease in the study by Taroni et al., while it did not
vary significantly in the study of Blackmore et al.
Over the years, the DOSI system developed at the University
of California, Irvine,51 has also provided pieces of information
on breast tissue composition affected by menopausal status. A
recent example is represented by the study performed to monitor
changes in tissue composition in 28 breast cancer patients under-
going neoadjuvant chemotherapy (see Sec. 4.4). In that case,
baseline (pretherapy) water and lipid content in breast tissue
was shown to depend markedly on the menopausal status, in
agreement with what described above, and also to correlate
with fibroglandular density assessed by MRI.
It is important to stress that optically derived data reported
in the literature on tissue composition and structure and their
changes are fully consistent with the present knowledge on
breast physiology, which has often been obtained through
ex vivo analyses or studies performed with invasive or more
complex and expensive approaches than optical ones (e.g., x-ray
mammography and MRI, respectively). The good correspon-
dence between optically derived information and medical
knowledge, combined with well-known and already mentioned
advantages of optical means (including noninvasiveness, limited
costs, good patient acceptance), indicates that optical spectroscopy
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could take on an effective role to investigate breast physiology in
vivo and monitor changes in breast tissue through longitudinal
studies (e.g., during chemotherapy or with age).
5 Emerging Fields in the Realm of Breast
Imaging and Spectroscopy
5.1 Photoacoustic Mammography
PI (or optoacoustic imaging) of the breast combines the high
contrast arising from light absorption in tissue with the high spa-
tial resolution associated with ultrasound detection. The local
absorption of light by tissue chromophores or contrast agents
leads to thermoelastic expansion of the tissue and to the forma-
tion of pressure waves. From the detected ultrasound signals, the
location of the absorbers can be estimated with superior spatial
resolution compared to diffuse optical imaging. At present,
photoacoustic mammography relies essentially on blood con-
trast and, hence, carcinomas and benign lesions can be detected
due to the increase in local deoxy-, oxy-, and total hemoglobin
concentration associated with angiogenesis of these lesions.
Although a laser optoacoustic imaging system for the breast was
proposed by Oraevsky et al.205 as early as in 1996, only more
recently clinical systems have been applied in exploratory stud-
ies. Here, we will shortly report on the main features of breast PI
prototypes. An extensive survey has recently been performed by
Menke.206
The most recent clinical studies have been performed using
the Twente Photoacoustic Mammograph. In the latest version of
this prototype,207,208 the patient is lying in prone position with
the breast pending through an aperture and mildly compressed
between a glass window and an ultrasound detector array con-
taining 588 elements. The breast is illuminated through the glass
plate by a pulsed laser at 1064 nm with 10-ns pulses at a rep-
etition rate of 10 Hz using a beam diameter of ∼70 mm. Infor-
mation from x-ray mammograms and ultrasound images are
used to define a region of interest on the breast, which is then
scanned by the laser beam. Depending on penetration depth, the
lateral resolution, and the axial resolution range from 2.3 to
3.9 mm and from 2.5 to 3.3 mm, respectively.207–209
The case studies performed over a period of 8 years on a total
of 23 patients with breast tumors have shown tumors with high
imaging contrast. In the most recent study on 11 patients,207 with
MRI data available, excellent correspondence in lesion localiza-
tion was found between PI and MRI images, together with a
good to reasonable correlation in lesion shape and appearance.
Moreover, it is important to notice that PI images were not
affected by the breast density. In patients with cysts (six
cases), the lesion was visible with high contrast only at the front
and/or at the back of the cyst where impedance changes occur,
leading to possible misdiagnosis since malignancies can also
appear as one or multiple confined contrast areas.208,210
The Canon prototype presented a configuration similar to
that of the Twente mammograph with respect to patient position
and breast compression geometry.211 The illumination system
was different and relied on two sources to provide forward and
backward illumination with respect to the 345 element array
transducer. The forward and backward laser pulses could
be applied simultaneously to maximize optical fluence in the
region of interest or alternately to evaluate forward and back-
ward images separately. The laser source was a tunable Ti:
Sapphire laser (15-ns pulses at 10-Hz repetition rate). The lateral
resolution was 2 to 3 mm. Clinical data were obtained from 26
patients with breast cancer. Images were acquired at both 756-
and 797-nm wavelengths to evaluate total hemoglobin content
and oxygen saturation. The tumors were correctly detected in
20 cases. The PI images showed high contrast related to the
higher hemoglobin content, with tumor margins less defined
as compared to MRI images.
The original laser optoacoustic imaging system (LOIS) pro-
posed by Oraevsky et al.212 was further developed to perform
optoacoustic tomography (LOIS-64).213 With the patient in
prone position, the uncompressed breast was suspended through
a circular hole in a probe cup. An arc-shaped 64 elements ultra-
sound transducer array was rotated around the breast to acquire a
set of 2-D images each with a depth resolution of 0.5 mm. The
expanded laser beam was provided by a Q-switched Alexandrite
laser emitting at 757 nm, with pulse duration of 75 ns at a rep-
etition rate of 10 Hz. In the clinical study performed on 27
patients, the LOIS-64 prototype revealed 18 out of 20 histologi-
cally proven malignant lesions and 4 out of 8 benign lesions.
In all cases detected, the tumor area presented high contrast
attributed to high tumor vascularization.
Although not yet tested on breast cancer patients, the
OptoSonics 512 prototype presents interesting features.214
With the patient in prone position, the breast is placed in a
spherical cup, designed to be optically transparent and with an
acoustic transmittance larger than 70% at 2 MHz. This cup is
positioned in a hemispherical bowl equipped with 512 ultra-
sound transducers (3 mm × 3 mm size). The pendant breast
being pushed toward the chest wall by the cup is illuminated
from below by an Alexandrite laser at 756 nm with a pulse rep-
etition rate of 10 Hz. The system was tested on four healthy
volunteers with breast thickness between 2.3 and 4 cm. The
reconstructed images clearly showed the breast vasculature with
Table 3 Dependence of tissue composition and structure (mean SD) on menopausal status (N ¼ number of subjects, N.A. = not available).
References Menopausal status Water (%) Lipid (%) Collagen (%) HbT (μM) StO2 (%) a (cm−1) b (—)
Blackmore
et al.117
Pre- (N ¼ 95) 21.3 7.2 61.5 10.2 N.A. 15.7 4.8 70.5 7.6 14.6 3.4 0.35 0.31
Post- (N ¼ 107) 18.2 5.9 68.3 9.0 N.A. 12.4 4.7 68.5 8.0 12.9 2.9 0.38 0.26
Water (mg∕cm3) Lipid (mg∕cm3) Collagen (mg∕cm3) HbT (μM) StO2 (%) a (cm−1) b (—)
Taroni
et al.204
Pre- (N ¼ 93) 263.1 148.4 598.3 133.5 98.73 43.0 13.6 4.1 86.8 9.6 14.9 2.6 0.70 0.27
Post- (N ¼ 102) 127.9 86.3 730.0 111.2 64.3 34.1 10.4 3.2 84.9 9.1 12.4 2.5 0.53 0.24
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submillimeter resolution. The estimated spatial resolution of the
system is 0.42 mm and, based on the phantom study, the authors
expect to be able to image tissues as thick as 5.3 cm.
The features of the presently available clinical prototypes
illustrate the potential of the photoacoustic approach. Several
problems, however, are still open ranging from technical aspects
(e.g., detectors sensitivity, field of view), the methodology of the
reconstruction algorithms, and the biological basis for discrimi-
nating malignant from benign lesions. Clearly, larger clinical
studies on both malignant and benign lesions are needed. As for
diffuse optical imaging and tomography, improvements might
come from multispectral operation and/or integration with other
diagnostic modalities, as, e.g., diffuse optical imaging/tomogra-
phy and ultrasound imaging, to combine information on tissue
properties from different approaches. Examples of these inte-
grated modalities are already present in the literature with
tests on phantoms or ex vivo specimens.215–217
A further proposed approach is related to the development of
handheld photoacoustic devices, which have the advantage to be
simple, portable, and can be easily integrated in an ultrasound
probe.218–220 As for other diagnostic modalities, improvements
might come from molecular imaging. In fact, suitable chromo-
phores might enhance the sensitivity and specificity of the
diagnostic images, which presently rely essentially on blood
contrast.221 Similarly, in hybrid ultrasound and photoacoustic
systems, ultrasonic contrast agents can be useful for both
modalities.
5.2 Long Wavelength Broadband Spectroscopy
Up to now, multiple-wavelength and broadband imaging and
spectroscopy of the breast have been performed at most up to
1000 to 1100 nm. However, it is interesting to observe that the
spectral range available for tissue spectroscopy is extending
toward longer wavelengths, up to 2 μm and beyond. The total
attenuation coefficient was measured ex vivo on thin (200 μm)
slices of breast tissue (healthy and cancerous) between 400 and
2500 nm, showing that in the second (1100 to 1350 nm) and
even more in the third (1600 to 1850 nm) NIR optical window,
deeper light penetration can be achieved compared to the con-
ventional first NIR window (650 to 950 nm). Moreover, in the
second and third windows, the scattering becomes progressively
less than in the first window, and light attenuation is dominated
by tissue chromophore absorption, suggesting the possibility to
perform imaging with reduced blurring with respect to what typ-
ically observed in diffuse optical images.222 Moreover, it has
been reported that fitting tissue composition and scattering
parameters over an extended spectral range (500 to 1600 nm
instead of 500 to 1000 nm), which includes more spectral fea-
tures, can significantly improve the results (i.e., the confidence
level on the estimate of water and lipid fractions can improve by
a factor of 4).223 Recent advances in laser sources, especially
supercontinuum fiber sources, and detectors have made it pos-
sible to develop portable systems and apply them to perform
diffuse optical spectroscopy in clinical settings at least up to
1350 nm,224 suggesting that results on in vivo breast studies
beyond 1000 to 1100 nm will soon become available.
6 Conclusions
During the last 20 years, tremendous amount of work has been
carried out on in vivo optical imaging of the female breast.
Starting from attempts to obtain high-contrast images of breast
carcinomas by a noninvasive and comparably cheap method,
the focus of research moved more and more to the development
of methods suited to quantitatively measure the functional
parameters of breast tissue and to understand the origin of con-
trast in near-infrared images of diseased as well as healthy
breast tissue. The present knowledge on functional and scatter-
ing properties shows why the initial idea to find carcinomas
and to distinguish them from benign lesions due to contrast
in hemoglobin concentration and oxygen saturation was not
successful. Locally increased hemoglobin concentration is
not only a feature of cancer but also of many benign tissue
alterations, and oxygen saturation of carcinomas is not suited
for their differentiation, at least if no detailed information on
perfusion is available. Improved spectral resolution has shown
that water, lipid, and collagen content and also scattering prop-
erties are different between cancer and healthy breast tissue. In
the future, long wavelength broadband spectroscopy extending
tissue optical spectroscopy further into the infrared spectral
range offers to more accurately determine concentrations of
the tissue constituents. Furthermore, DCS has shown that
the blood flow index is another promising quantity to differ-
entiate carcinomas from healthy tissue, in particular, when a
detailed physical model for the loss of correlation becomes
available.
Currently, sensitivity and specificity of optical mammogra-
phy are likely too low for its application as a screening tool.
More importantly, the poor spatial resolution of diffuse optical
imaging prevents early detection of breast cancer, which is a
main aim of screening. Although PI may overcome this limita-
tion, it is an open question, whether the stringent requirements
for screening of high sensitivity, high specificity, and high
patient throughput can be met by this modality. Instead, the
unique capabilities of optical breast imaging offer high potential
for its use as an adjunct modality in diagnostic mammography
and as a tool for monitoring cancer therapy. Hereby, known
lesions in the breast are characterized by their functional param-
eters. With respect to diagnosis, this additional information
could possibly help to reduce the number of biopsies that are
necessary for assessing malignancy of suspicious lesions and
to avoid frequent false positive results. Several clinical studies
have shown improved sensitivity and specificity of conventional
imaging modalities, when known lesions are additionally char-
acterized by functional parameters from near-infrared spectros-
copy. Currently, the power of the various functional properties,
including scattering parameters, is differently assessed by vari-
ous research groups, which is evident, e.g., from the various pro-
posed tissue optical indices. Future work should aim at a more
comparable database to select the properties with the highest
potential for differentiation, and to identify preferred approaches
of tumor assessment for specific subgroups of patients.
Besides the intrinsic tissue contrast, optical contrast agents
are of high potential for the differentiation of suspicious lesions.
The EPR effect using plasma proteins labeled with the fluores-
cent marker ICG offers a unique method to assess the leakiness
of the tumor vasculature. Quantitative results on ICG extrava-
sation are also of interest for intraoperative fluorescence detec-
tion of tumor margins using ICG, an approach starting to play a
role in breast-conserving cancer surgery. Furthermore, the detec-
tion of weak fluorescence signals demonstrated with the avail-
able contrast agents indicates that other fluorescent molecular
agents could be detected, once they become available. Depend-
ing on the power of such agents, new applications of fluores-
cence breast imaging could arise.
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Looking toward the different research activities associated
with optical breast imaging, monitoring the patient’s response
to NAC seems to be closest to clinical translation. Available data
show strong evidence that early evaluation of the response to the
treatment should allow one to predict success or failure of NAC.
Another potential application of near-infrared spectroscopy of
the breast is the evaluation of breast density as a risk factor for
developing cancer. Although totally different with respect to tar-
get groups, both applications offer ways toward a personalized
therapy using optical breast imaging.
Photoacoustic mammography offers the advantage to image
the breast with superior spatial resolution compared to diffuse
optical imaging. In particular, vascular structures can be resolved
even deeply inside the breast with higher resolution as can be
achieved with diffuse optical mammography. At present, potential
of photoacoustic mammography for detection and characteriza-
tion of breast carcinomas and benign lesions has not been evalu-
ated yet, and image contrast is based on the same absorbing tissue
volumes, chromophores, or contrast agents that are used in diffuse
optical imaging. Tissue scattering properties and sensitive fluores-
cence detection are not accessible by this method.
In order to better understand the origin of host-tumor contrast
in near-infrared breast images or tissue spectra, advanced tissue
models are needed.225,226 The remodeling of vasculature, lym-
phatics, ECM, and the invasion of cells of different origin
caused by the presence of carcinoma represent complex, in
part chaotic biological processes that are presently being unrav-
eled by tumor biology. Such processes alter, e.g., vascular
morphology, biochemical composition, and mechanical as
well as scattering properties of the ECM. Furthermore static
and dynamical physical measures, such as perfusion, interstitial
flow, as well as solid and interstitial fluid pressure, are affected.
Such changes bear on the quantities that can be measured by
optical mammography and breast tissue spectroscopy. To fully
exploit the information contained in clinical data, improved tis-
sue models are needed, which in turn can be further improved by
including clinical results. Such models will contribute to a better
understanding of physical processes associated with tumor
pathophysiology and, eventually, will add to better treatment.
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